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A B S T R A C T
Anticytokine strategies probably represent the most
important breakthrough in the treatment of inflammatory
diseases in the last decade. However, blocking the bio-
activity of proinflammatory cytokines, crucial activators of
host defence, has proved to be accompanied by an
increased susceptibility to infections, especially with
Mycobacteria, Salmonellae and fungal pathogens. Multiple
mechanisms for these side effects have been proposed,
such as inhibition of gamma-interferon production,
decreased expression of pattern-recognition receptors,
and leucocyte apoptosis. Caution is therefore warranted
when these treatments are given to patients with an
increased risk for infections. A range of side effects other
than infection have been reported.
Treatment strategies interfering with proinflammatory
cytokines such as tumour necrosis factor (TNF)  and
interleukin-1 (IL-1) constitute a breakthrough in the
treatment of rheumatoid arthritis (RA) and other
inflammatory disorders. However, some 10 to 15 years
ago it was demonstrated in experimental animals that
treatment with antibodies against TNF was deleterious in
mycobacterial infections, fungal infections and abscesses.
The exact mechanisms by which interference with TNF
produced these results were not entirely clear, but it was
concluded that containment of micro-organisms within
granulomas and abscesses was not achieved or main-
tained.1-3
Based on these observations, it was easy to predict that
large-scale and prolonged anti-TNF treatment in humans
would lead to infections, especially by organisms that
induce a granulomatous response. Indeed, such com-
plications (especially mycobacterial and Salmonella
infections) were readily encountered, but still seemed to
come as a surprise to the medical community. 
In this issue of the journal, Efde and colleagues report a
case of tonsillar tuberculosis, a rare manifestation of this
infectious disease, occurring during anti-TNF treatment.4
The occurrence of these infections has important impli-
cations for pretreatment assessment of patients, and
guidelines for this purpose are appearing, also in the
Netherlands.5 Two years ago, the Netherlands Journal of
Medicine published a state-of-the-art review by Arend et al.
on this topic with a detailed account of the literature
and a proposal for the management of patients at risk.6
The patient reported in this issue of the journal received
a six-month course of isoniazid for latent tuberculosis.
As noted in the review6 and by the authors of the case
report,4 a period of six months of isoniazid is not optimal.
It also implies that the risk of reactivation of tuberculosis
during anti-TNF treatment in patients harbouring dormant
bacilli should not be underestimated.
It is interesting that the risk for infection is greater with
the monoclonal antibodies against TNF (infliximab and
adalimumab) than with the TNF receptor construct
etanercept: during infliximab therapy the risk is estimated
to be 200 per 100,000 treatments, with etanercept it is 9
per 100,000.7 Theoretically, one would expect differences
between the various types of anti-TNF drugs, as they dif-
fer in their capacity to interact with TNF- and TNF-
(lymphotoxin), and with membrane-bound TNF. Another
© 2005 Van Zuiden Communications B.V. All rights reserved.
E D I T O R I A L
Side effects of anticytokine strategies
J.W.M. van der Meer*, C. Popa, M.G. Netea**
Departments of General Internal Medicine and Rheumatology, Nijmegen University Centre for
Infectious Diseases, Radboud University Medical Centre, Nijmegen, the Netherlands, 
*corresponding author, **temporary address: University of Colorado Health Sciences Center,
Colorado, USA
Advertentie Pharmaphone
interesting, not well-explained observation is that treatment
with the recombinant interleukin-1 receptor antagonist,
IL-1Ra (anakinra), does not seem to lead to excess infection.
How inhibition of TNF impairs host defence in patients
is still enigmatic, but several mechanisms have been
suggested. Firstly, blockade of TNF itself can impair host
defence, as TNF is known to activate the microbicidal
properties of neutrophils and macrophages.8 Secondly,
TNF blockade can inhibit secondary activation of the
cytokine cascade. We have demonstrated in patients with
a serious Salmonella infection that interferon- production
was strongly inhibited.9 The role of the latter cytokine in
host defence against micro-organisms is much better
understood: a deficient response to this cytokine has
been shown to lead to serious infections.10-12 Important
questions that remain are whether all patients who receive
anti-TNF treatment respond with a down-regulation of
the interferon- response, and whether we can predict the
risk for infection by assessing the production of this
cytokine. It is also tempting to speculate that the capacity
to down-regulate the interferon- response explains the
difference in occurrence of infection between IL-1 inhibition
and TNF inhibition, but more research is needed to answer
this question. Other mechanisms of anti-TNF treatment
include down-modulation of pattern recognition receptors
such as TLR4,9 and leucocyte apoptosis.13 One may also
ask the question whether anticytokine treatment, for
example in patients with rheumatoid arthritis, has more
effects that are not intended. A range of side effects other
than infection have been reported, albeit with a lower
incidence.14
Treatment with TNF inhibitory agents has been associated
with rare cases of onset or exacerbation of demyelinating
disorders, which met with a partial or complete response
when treatment was stopped. In addition, despite the
elevated TNF concentrations in the cerebrospinal fluid
and in the circulation of multiple sclerosis (MS) patients,
blocking this cytokine resulted in a worsening of the
disease.15 The mechanisms underlying this side effect are
still unknown. 
Development of autoantibodies including antinuclear
antibody (ANA) and anti-double-stranded DNA have been
reported during therapy with anti-TNF agents. The clinical
relevance of this is uncertain, although post-marketing
surveillance reports mention cases of autoimmune diseases,
especially leucocytoclastic vasculitis and lupus-like syndrome,
improving after therapy was discontinued. 
Concerns have been raised about haematological disorders,
especially non-Hodgkin’s lymphoma, and cytopenia during
anti-TNF therapy. Very few cases have been reported in
patients with long-lasting RA receiving multiple drugs.
The role of anti-TNF drugs is therefore unknown.
Congestive heart failure proved to worsen by TNF blockade,
despite earlier studies predicting the opposite: chronic heart
failure (CHF) was associated with elevated production of
TNF. Trials intended to show the benefit of suppressing
TNF in CHF patients met with increased mortality in the
anti-TNF group compared with placebo.16 However, one
should be prudent when interpreting the onset of CHF in
patients with RA receiving anti-TNF therapy, as cardio-
vascular diseases are a leading cause of death among
these patients.
Perhaps more interestingly, therapy of RA patients with
TNF blockers might also have beneficial consequences,
other than those related to the inflamed joints. 
An increased mortality due to cardiovascular and cerebro-
vascular diseases is seen in RA patients when compared
with the general population. The contribution of inflam-
mation to the development of atherosclerosis and insulin
resistance is now regarded to be more and more important,
and TNF has emerged as playing a key role in these
processes. In addition, markers of inflammation, such
as C-reactive protein (CRP), are now considered to be
important predictors of future acute cardiovascular
events. In that respect, we recently investigated whether
the profile of cardiovascular risk factors in such patients
ameliorates during anti-TNF treatment.17 This would not be
unexpected, since TNF is known to increase interleukin-6
(IL-6) and CRP and induce proatherogenic changes in
lipid profile. 
We found that anti-TNF treatment with adalimumab
enhanced the concentrations of HDL cholesterol and
decreased the concentrations of CRP and IL-6 within 
14 days. To what extent these changes remain during
prolonged observation and translate into a lower cardio-
vascular risk is the subject of future studies.
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A B S T R A C T
This article presents a review of the treatment of lower-
extremity deep venous thrombosis (DVT) with systemic
and catheter-directed thrombolysis (CDT) and percutaneous
mechanical thrombectomy (PMT). Standard treatment
including anticoagulation therapy and compression stock-
ings may not be entirely adequate, because a significant
proportion of patients eventually develop post-thrombotic
syndrome (PTS). Thrombolytic agents might offer a
potential advantage because they cause faster and more
complete clot resolution, which may reduce or prevent
residual vein stenosis and valve damage.
Thrombolytic therapy results in greater lysis, but also in
higher complication rates than does anticoagulation
alone. Major bleeding occurs in 11% of patients treated
with thrombolytic therapy. The incidence of PTS tends to
be lower in patients treated with thrombolytics. However,
several methodological flaws limit the conclusions with
respect to reduction in PTS.
No adequate randomised controlled trials have been
performed comparing CDT or PMT with conventional
therapy. Given the current data, thrombolytic treatment,
CDT or PMT should not be applied except in extraordinary
cases. First, the long-term effectiveness in terms of reducing
PTS, although possible, remains uncertain. Second, the
risks of thrombolytic therapy and PMT are higher. Third,
current conventional therapy is relatively inexpensive,
convenient and safe.
I N T R O D U C T I O N
Deep venous thrombosis (DVT) is an important disease
with serious clinical sequelae. Its annual incidence is one
per 1000 patients, but the incidence increases with age.1-3
The therapeutic goals for treating the patient with acute
DVT include prevention of pulmonary embolism (PE),
prevention of recurrent thrombosis and preservation of
venous valve function. Success in the achievement of these
clinical goals will minimise the morbidity and mortality
of PE and will diminish the long-term sequelae of the
post-thrombotic syndrome (PTS). 
The current standard of care includes systemic anti-
coagulation with unfractionated heparin (UH) or low-
molecular-weight heparin (LMWH) followed by oral anti-
coagulants.4,5 Such a regimen, however, does not promote
lysis to reduce the thrombus load, nor does it contribute to
restoration of venous valve function. Anticoagulation alone,
therefore, might not sufficiently protect the limb from PTS.
Catheter-directed thrombolysis (CDT) and percutaneous
mechanical thrombectomy (PMT) have been proposed as a
new treatment for patients with DVT. Application of these
techniques could potentially result in a lowering of the PTS
syndrome by preservation of the venous valve function.
This article provides a comprehensive review of the literature
evaluating the efficacy and safety of systemic thrombolysis and
CDT and PMT in patients with DVT, with the focus on PTS. 
C L I N I C A L  C O N S E Q U E N C E S  O F  D V T
In the acute phase, venous obstruction leads to impaired
venous return and therefore most patients experience leg
© 2005 Van Zuiden Communications B.V. All rights reserved.
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pain and swelling. Patients with extensive thrombosis may
experience more severe symptoms and on rare occasions
develop limb-threatening ischaemia. PE, with its attendant
mortality, is the most devastating complication of acute
DVT.6 Chronically, DVT results in a variable degree of
venous obstruction and valvular incompetence. These
changes can lead to PTS.7
Pathophysiology of PTS
PTS refers to a spectrum of post-thrombotic chronic
venous diseases attributable to venous hypertension and
stasis affecting a limb in which a DVT has previously
occurred. The spectrum of PTS can encompass several
combinations of symptoms in various degrees of severity.
These include a chronic feeling of leg heaviness, leg aching
and venous claudication, oedema, venous varicosities,
and chronic trophic skin changes ranging from hyper-
pigmentation to frank nonhealing ulceration to fibrotic
scarring.8-10
The pathophysiology is thought to be multifactorial,
including venous obstruction and valvular incompetence;
inflammatory damage caused by the thrombotic process
and subsequent scarring is a likely mechanism. Valvular
incompetence develops most frequently in segments
affected by thrombosis and seldom develops in segments
initially free of thrombus, with total thrombotic occlu-
sions resulting in the highest risk for subsequent valve
insufficiency.11-14 Unlike valvular incompetence, which
can develop shortly after acute DVT, the onset of derma-
tological manifestations of PTS tends to be much more
delayed, with symptoms usually occurring within two
years after the initial DVT episode.9,15,16
C O N V E N T I O N A L  A N T I C O A G U L A N T
T H E R A P Y
Current conventional treatment of DVT consists of anti-
coagulation and the use of compression stockings.
Anticoagulation therapy consists of subcutaneous LMWH
or intravenous UH initially, followed by oral anticoagulants.
LMWH is continued for at least five days and coumarin
therapy for at least three months, the total duration varying
according to underlying risk factors for recurrence. In
general, this approach to treatment is effective and safe in
most patients.4,17-20 Anticoagulation therapy has no direct
thrombolytic effect, and thrombus recanalisation largely
depends on the effectiveness of the endogenous fibrinolytic
system and the initial thrombus load. The risk of major
complications in large randomised trials of LMWH is low:
fewer than 5% have recurrent venous thromboembolic
events, fewer than 2% have clinically significant bleeding,
and fewer than 2% have symptomatic PE.4,18,21,22
No major randomised trials of treatment in the initial
phase have included PTS as a primary endpoint.
Adjunctive treatments such as compression stockings
have been shown to reduce the incidence of the PTS by
50%.23 However, a risk of moderate to severe PTS of
about 10% is reported in patients who receive appropriate
anticoagulation and compression therapy. Proponents of
thrombolytic therapy argue that this rate is high enough
to warrant interventional treatment strategies.24,25
M E T H O D S
Nonconventional thromboablative types of therapy in
acute DVT include systemic thrombolytic therapy,
catheter-directed regional thrombolytic therapy (CDT)
and percutaneous mechanical thrombectomy (PMT). 
A study using the electronic literature (PubMed) was 
performed using the keywords deep venous thrombosis,
thrombolysis, catheter-directed thrombolysis and mechanical
thrombectomy. Literature was reviewed up to January 2004.
Eighteen controlled trials were identified comparing sys-
temic thrombolytic therapy with standard treatment.26-42
Twelve studies compared streptokinase with heparin
(468 patients), two trials compared urokinase with heparin
(117 patients) and four trials compared tissue plasminogen
activator with heparin (150 patients). There were eight trials
reporting the incidence of PTS after thrombolysis. Only one
trial compared catheter-related thrombolysis with standard
anticoagulant treatment.43 There are no trials comparing
PMT and conventional therapy. For this reason also non-
randomised trials evaluating CDT and PMT are discussed.
S Y S T E M I C  T H R O M B O L Y T I C  T H E R A P Y
The rationale for an aggressive thromboablative approach
in acute DVT might be twofold. In the short term, it
consists of preventing PE, achieving rapid reduction of
pain and swelling of the involved leg, and, when applicable,
preventing or allowing more effective management of
phlegmasia cerulea dolens and venous gangrene. The
long-term endpoint of treatment of an acute DVT episode
relates mainly to the prevention of PTS. Rapid thrombus
resolution may offer a potential for prevention of PTS
based on the known favourable effect on the preservation
of venous valvular function. It might also prevent the
development of obstructive disease because it prevents
organisation of an occlusive thrombus, which leads to
downstream venous hypertension. 
Tables 126-42 and 229,38,39,44-48 show a summary of the randomised
controlled trials that have compared lytic therapy with
standard heparin in the acute phase and in the long-term.
It has to be noted that there are no trials comparing
thrombolytic therapy with LMWH.
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Short-term efficacy
The results of randomised controlled trials assessing the
short-term efficacy of streptokinase, urokinase and rt-PA
compared with heparin are summarised in table 1.26-30,32,33,35-41,48
Most of these trials demonstrate that systemic thrombolytic
therapy more often leads to complete or partial resolution
than does heparin therapy. Complete lysis occurred in
26 to 67% and 0 to 22% of patients, respectively.
Although at least some degree of lysis has been reported
in 50 to 70% of patients treated with thrombolysis, no
single study has had sufficient power to prove its 
efficacy in comparison with standard anticoagulation. 
Previous studies suggest that newer and nonocclusive
thrombi are more likely to undergo successful lysis when
compared with older and occlusive thrombi.49
Long-term efficacy
Eight studies (173 patients) were identified comparing
lytic therapy with UH in which long-term efficacy was
assessed.29,38,39,44-48,50 An additional study has been published
in which patients were randomised to one of several
thrombolytic regimens or UH (250 patients).39 Duration
Table 1
Randomised trials comparing systemic thrombolytic and heparin therapy for deep venous thrombosis
NUMBER VENOGRAPHIC RESULTS 
(RESOLUTION)
AUTHOR TOTAL EVALUBLE TREATMENT COMPLETE PARTIAL NONE MORTALITY PE MAJOR 
(YEAR) N (%) N (%) N (%) N (%) N (%) BLEEDING
N (%)
Browse 10 5 Heparin 0 0 5 (100) 0 0 0
(1968) 5 SK 3 (60) 1 (20) 1 (20) 0 0 0
Robertson 16 8 Heparin 0 3 (37) 5 (63) 1 (10) ND 1 (13)
(1968) 8 SK 0 7 (87) 1 (13) 0 ND 3 (38)
Kakkar 20 9 Heparin 2 (22) 2 (22) 5 (56) 2 (20) 1 (10) 2 (20)
(1969) 9 SK 6 (67) 1 (11) 2 (22) 0 0 2 (20)
Robertson 16 7 Heparin 2 (29) 5 (71) 0 0 1 (14)
(1970) 9 SK 6 (67) 3 (33) 1 (11) 4 (44) ND
Tsapogas 34 15 Heparin 1 (7) 14 (93) 0 1 (7) ND
(1973) 19 SK 10 (53) 9 (47) 0 0 ND
Duckert* 134 42 Heparin 0 4 (10) 38 (90) 0 5 58 (62)
(1975) 92 SK 39 (42) 23 (25) 30 (33) 0 7 2 (5)
Porter 50 26 Heparin 1 (4) 20 (77) 5 (19) 0 0 1 (4)
(1975) 23 SK 6 (26) 15 (65) 2 (9) 1 (4) 0 4 (17)
Marder 24 12 Heparin 0 3 (25) 9 (75) 0 ND ND
(1977) 12 SK 5 (42) 2(16) 5 (42) 1 ND ND
Arnesen 42 21 Heparin 5 (24) 16 (76) 0 0 3 (14)
(1978) 21 SK 15 (71) 6 (29) 0 1 (5) 3 (14)
Eliott 51 25 Heparin 0 ND ND 2 (8) 2 (8) 0
(1979) 23 SK 9 (39) 12 (52) 2 (9) 0 1 (4) 2 (8)
Watz 35 17 Heparin 1 (6) 5 (29) 11 (65) 0 1 0
(1979) 18 SK 8 (44) 4 (22) 6 (34) 0 1 0
Schulman 38 19 Heparin 2 (11) ND ND 0 0 1 (5)
(1986) 17 SK 7 (41) ND ND 0 0 3 (18)
Jeffrey 40 20 Heparin 1 (5 0 19 (95) ND ND ND
(1986) 20 SK 11 (55) 0 9 (45) ND ND ND
Turpie I 24 12 Heparin 2 (17) 10 (83) 0 ND 1 (8)
(1990) 12 rt-PA 9 (75) 3 (25) 0 ND 4 (33)
Turpie II 59 30 Heparin 7 (23) 23 (77) 0 ND 1 (3)
(1990) 28 rt-PA + heparin 13 (46) 15 (54) 0 ND 1 (3)
Goldhaber 65 11 Heparin 0 2 (18) 9 (82) 0 ND 0
(1990) 32 rt-PA 2 (6) 18 (56) 12 (38) 0 ND 1 (3)
17 rt-PA + heparin 1 (6) 8 (47) 8 (47) 0 ND 0
Goldhaber 361 9 Heparin 1 5 3 0 ND 1
(1996) 8 rUK 1 5 2 0 ND 0
Schweizer 150 50 Heparin 1 (2) 9 (18) 40 (80) 0 0 0
(2000) 50 UK + heparin 17 (34) 23 (36) 10 (20) 0 4 (8) 4 (8)
50 SK + heparin 20 (40) 20 (40) 10 (20) 0 5 (10) 5 (10)
PE = pulmonary embolism; SK = streptokinase; UK = urokinase; rUK = recombinant urokinase; rt-PA = recombinant tissue plasminogen activator; 
ND = not determined; *not randomised.
of follow-up varied from two months to six years. Most of
the studies invariably did not use a validated scoring system
for assessment of PTS, but relied on clinical assessment.
These assessments were performed at different intervals
in each study and were not always blinded to the treatment
allocation, and in some of the trials assessments were
limited because of significant numbers of patients lost to
follow-up.
Aggregating the data from these studies, the long-term
risk of developing PTS in the thrombolytic groups is 0 to
80%, whereas in the unfractionated heparin group it is
40 to 90%. 
The largest study demonstrated relatively poor functional
results (low reflux pathology) in heparin control patients,
giving rise to more symptoms of PTS.39 They also
observed that patients affected by thromboses in the
pelvic region seemed to benefit less from lytic treatment,
which is known due to early collateral formation. Lysis
medication may, thereby, fail to reach thromboses in
pelvic veins due to circulatory bypasses. 
Complication rates
Potential complications of thrombolytic therapy include
bleeding and PE. In a meta-analysis Lensing and Hirsh
reported major bleeding events in 13.2% of patients treated
with systemic streptokinase or recombinant tissue plasmin-
ogen activator (rt-PA) compared with 3.5% of patients treated
with heparin. Systemic treatment with rt-PA resulted in
one major haemorrhage for every 15 patients treated.51
Aggregating the data across studies in table 1 shows that
9% (range 0 to 38%) of patients receiving thrombolytic
agents have a major bleed compared with only 5% (range
0 to 22%) of patients receiving UH. The wide range can
be explained by more aggressive diagnostic and follow-up
protocols in earlier studies and by the variable definitions of
‘major haemorrhage’. There was no significant difference in
bleeding risk according to route of administration or dose.
Haemorrhage following thrombolytic therapy most
commonly occurs at vascular puncture sites, although
spontaneous haemorrhage, especially gastrointestinal,
retroperitoneal and intracranial, may also occur. Older
age, a higher body mass index, and the performance of
pulmonary angiography have been identified as significant
predictors of bleeding.
Before initiating thrombolytic therapy, patients should
undergo a thorough evaluation to elicit factors that
increase the risk of major haemorrhage. A striking study
is that of Markel et al.52 in which only 15 (7%) of 209
patients with DVT exhibited no contraindications for
thrombolytic treatment. 
Risk of PE while receiving the thrombolytic agent is a
theoretical concern. Lensing and Hirsh demonstrated
that in contrast to the haemorrhagic risk, the incidence of
clinically significant PE was quite low.51 However,
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Table 2
Long-term results of systemic thrombolytic therapy
RESULTS
VENOGRAMS
AUTHOR NUMBER OF PATIENTS DURATION OF FUNCTIONAL CLINICAL
(YEAR) INITIAL LONG-TERM FOLLOW-UP TREATMENT NORMAL N (%) PTS* N (%) PTS N (%)
Kakkar 20 8 6-12 months Heparin 1 (13) 7 (87) ND
(1969) 7 SK 4 (57) 3 (43) ND
Bieger 10 5 3-4 months Heparin 1 (20) 4 (80) 2 (40)
(1976) 5 SK 4 (80) 1 (20) 0
Common 50 12 4-18 months Heparin 1 (8) 11 (92) 6 (50)
(1976) 15 SK 6 (40) 9 (60) 5 (33)
Johansson 57 3 9-12 years Heparin 2 (66) 1 (33) 2 (66)
(1979) 5 SK 0 3 (100) 4 (80)
Elliott 51 20 19 months Heparin ND ND 18 (90)
(1979) 23 SK 10 (50) 10 (50) 8 (35)
Arnesen 42 18 6.5 years Heparin 0 18 (100) 12 (67)
(1982) 17 SK 7 (44) 9 (56) 4 (24)
Schulman 38 18 2-108 months Heparin 4 (36) 7 (64) 11 (61)
(1986) 17 SK 1 (14) 6 (86) 11 (65)
Schweizer 250 46 12 months Heparin 5 (11) 41 (89) 41 (89)
(2000) 46 SK (syst) + heparin 23 (50) 23 (50) 23 (50)
46 UK (syst) + heparin 14 (30) 32 (70) 32 (70)
50 UK (locoregional) + 13 (26) 37 (74) 37 (74)
heparin
50 Rt-PA + heparin 11 (22) 39 (78) 39 (78)
PTS = post-thrombotic syndrome; SK = streptokinase; UK = urokinase; rt-PA = recombinant tissue plasminogen activator, *measured using venography or duplex.
Schweitzer’s data suggest that there is an increased risk
as 4.5% of patients suffered a PE while on lytic therapy.39
Furthermore the prolonged infusion times (two to three
days) typically required to treat iliofemoral DVT can be
difficult to tolerate for some patients, and complications
may become more frequent with longer infusion durations.
Also the cost of thrombolytic infusion, multiple venograms,
repeat laboratory studies and the intensive care unit
monitoring required for thrombolytic therapy in many
centres is substantial.
Failure of lytic therapy
Reasons for lytic therapy to fail include extensive DVT in
which the plasminogen activator does not contact the clot;
old, organised thrombus; inadequate fibrinolytic
response; and premature termination of lytic infusion.49
The success of lysis is related to the amount of fibrin
bound to plasminogen within the thrombus and, therefore,
correlates with the age of the thrombus. Treatment of
patients whose thrombus is more than one week old is less
likely to be successful. Unfortunately, clinicians cannot
accurately determine the age of the clot but must rely on
patient’s symptoms, which in many cases are not closely
related.
In most centres only patients with extensive venous
thrombosis are treated with thrombolytic therapy.
Because these patients frequently have iliofemoral venous
thrombosis, they are likely to have the poorest long-term
outcome. This patient selection process represents an
inherent bias in evaluation of outcome based on therapy.
In such patients, the venous system is frequently occluded
by the thrombus and there is no blood flowing through
the veins involved. 
C A T H E T E R - D I R E C T E D  T H R O M B O L Y S I S
Local-regional thrombolytic therapy has emerged in the
past decade as a possible superior approach, allowing
delivery of the pharmacological thrombolytic agent directly
into the venous thrombus. This technique has evolved to
address the main limitations of systemic thrombolysis;
namely, unpredictability of thromboablative effect, high
risk for haemorrhagic complications and high rate of
patient exclusion from therapy because of the need to
adopt stringent selection criteria to avoid haemorrhagic
complications. 
The most common agents used are urokinase and rt-PA.
Two groups of techniques have been developed.53 The
first is catheter-directed thrombolysis, which relies on
administration of the thrombolytic agent directly into the
clot with use of a variety of infusion catheters or wires
and from various approaches. The second is flow-directed
regional thrombolytic therapy, which is based on the
direct regional infusion of concentrated thrombolytic
agent from an ipsilateral dorsal foot vein into the deep
venous system. Although the latter approach has the
advantage of allowing regional thrombolysis of the crural
veins, which are typically difficult to access with use of
catheter-directed techniques, it is more time-consuming
and requires larger doses of thrombolytic than catheter-
directed protocols.53,54 Postprocedurally, all patients should
be started on a long-term anticoagulation regimen with a
target INR of 2.5 to 3.0 for three months unless contra-
indications exist. 
Only one randomised controlled study comparing CDT vs
conventional therapy has been performed.43 This trial is
not reliable, since only 35 of 207 patients were included
in the study. For this reason also the nonrandomised trials
are being discussed (table 3).55-69
Several small series have demonstrated a high efficacy
rate, with reported complete or substantial recanalisation
rates of 60 to 83%.61-63,66,68,69 The success rate of CDT
appeared to be increased by adjunctive procedures such
as angioplasty, stent placement and mechanical
thrombectomy. So far, the largest published experience
with this approach in lower-extremity DVT has been
from the Venous Thrombolysis Registry, which reported a
collective multicentre experience with 287 patients (303
limbs) in whom one-year follow-up was available.60,70 The
location of DVT was in the iliofemoral segment in 71% of
patients with involvement of the inferior vena cava (ICV)
in 21%. Complete thrombolysis was achieved in 31% of
cases, whereas partial (>50%) thrombolysis with restoration
of forward flow was achieved in 52% of patients.
Complications included an 11% incidence of major bleeding
that required transfusion of blood products and a 16%
incidence of minor bleeding. The risks of intracranial
haemorrhage and death were 0.2 and 0.4% respectively.
Although the overall rate of valvular reflux on follow-up
was 58%, valvular reflux occurred in only 28% of patients
in whom complete thrombolysis was achieved. Comerota
et al. demonstrated that patients treated with CDT had
better functioning and well-being, compared with
patients treated with anticoagulation alone.71 Despite the
possible promise of the data, the Venous Registry was not
a randomised trial and lacked a control group treated with
standard anticoagulation. Therefore the data cannot be
used to establish a new standard of care for the treatment
of acute DVT.
The most common complication during CDT is bleeding,
either local from the access site or remote from onset of a
systemic thrombolytic state. Reported rates of major
bleeding requiring transfusion vary widely (0 to 25%),
depending on the dosing regimen, duration of infusion,
extent of concomitant anticoagulation and the specific
Janssen, et al. Local and systemic thrombolytic therapy.
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thrombolytic agent used. It has been shown that pro-
longed infusions are associated with increased frequency
of haemorrhagic complications, with intracranial bleeding
occurring in as many as 3% of patients receiving systemic
treatment.72,73 Other complications include PE, infections
and sepsis. The need for ICV filtration during endovascular
management of extensive DVT has been debated. 
Furthermore, although the medical literature indicates that
CDT of proximal venous thrombosis is quite successful
on a short-term basis, it does not address the long-term
issue PTS prevention.
P E R C U T A N E O U S  M E C H A N I C A L
T H R O M B E C T O M Y
Since outcomes might be optimised with maximum clot
removal, and because thrombolytic agents are less effective
on subacute or chronic thrombus, PMT has emerged as a
potentiator of pharmacological therapy. In addition, some
patients with absolute contraindications to pharmacological
thrombolysis may be candidates for mechanical lysis.
Many devices have been developed recently, most using one
of the following mechanisms to remove clot: rheolytic
aspiration, mechanical aspiration or ultrasonic lysis.
Some devices are designed to use both mechanical frag-
mentation and pharmacological lysis.74,75
The use of PMT might offer advantages in DVT. Flow
can be established more rapidly, even though achieving
complete or near-complete thrombus ablation often
requires a combination of pharmacological and mechanical
techniques. Furthermore it can be used primarily in 
situations in which rapid venous decompression and
restoration of flow is crucial.76
Technique
The extent of thrombus is determined by imaging with
ultrasound and computed tomography. Cross-sectional
images also reveal other pertinent anatomical factors
such as May-Thurner syndrome, osteophytes, tumours or
masses. Access is obtained peripheral to the thrombosed
segment and an anterograde approach is used. A single
wall puncture of the ipsilateral popliteal vein is made
under ultrasound guidance. If the popliteal vein is
thrombosed, the proximal posterior tibial vein may be
cannulated. Venograms are performed to delineate the
extent of thrombus. Combined mechanical thrombectomy
and pharmacological lysis can take place. 
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Table 3
Catheter-directed thrombolysis for DVT
AUTHOR N THERAPY MEAN  SIGN PARTIAL NO PTA STENT MAJOR PE DEATH
(YEAR) TIME OF RESO- RESO- RESO- N N BLEED- N N
LYSIS LUTION LUTION LUTION ING
(HR) N (%) N (%) N (%) N
Molina (1992) 12 UK 70 11 (92) 1 (8) 0 10 5 0 0 0
Palombo (1993) 6 rt-PA / * 6 (100) 0 0 0 0 0 0 0
heparin*
Emanuelli (1995) 25 UK/SK 48 17 (68) 8 (32) 0 0 0 0 0 0
Semba (1996) 32 UK 30 27 (84) 3 (9) 2 (6) 22 20 0 0 0 
Verhaeghe (1997) 24 rt-PA 30 19 (79) 5 (21) 0 0 9 6 0 0
Raju (1997) 24 UK 41 17 (71) 4 (17) 3 (12) 12 6 0 0
Bjarnason (1997) 77 UK 75 61 (79) 0 16 (21) 46 34 5 1 0
Mewissen (1999) 312 UK 53.4 258 (83) 54 (17) 0 ND 105 54 6 2
Comerota (2000) 54 45 (83) 0 9 (17) 6 0 0
Horne (2000) 10 rt-PA 24-72 9 (90) 1 (10) 0 0 0 1 2 0
Aburhama (2001) 18 UK 15 (83) 1 (5) 2 (11) 10 2 0 0
Chang (2001) 10 rt-PA 9 (90) 1 (10) 0 0 0 0 0 0
Elshawary (2002)** 17 Heparin 0 0 17 (100) 0 0 0 1 0
18 SK 11 (61) 7 (39) 0 1 1 0 0
Castaneda (2002) 25 Reteplase 23 (92) 0 2 (8) 13 1 0 0
Burkart (2002) 5 Tenecteplase 4 (80) 0 1 (20) 0 0 0 0
Cho (2003)*** 5 UK 5 (100) 0 0 2 0 0 0
Grunwald (2004) 38 UK 40.6 27 (71) 10 (26) 1 (3) 0 0 2 ND 0
32 tPA 30.8 21 (66) 10 (31) 1 (3) 0 0 1 ND 0
12 rPA 24.3 6 (50) 6 (50) 0 0 0 1 ND 0
UK = urokinase; rt-PA = recombinant tissue plasminogen activator; SK = streptokinase; ND = not determined; *rt-PA alternating with heparin infusion;
**randomised study (only 35 of 207 patients were included); ***patients with protein C and S deficiency.
There are no controlled studies comparing PMT and con-
ventional anticoagulant treatment. Recent trials evaluating
PMT are described in table 4.77-80 It has to be noted that
these studies evaluated only a small selection of patients.
Potentially significant complications with PMT are PE
and valve damage.74,78,81,82 Because the goal of treatment is
to improve quality of life by increasing the extent of lysis
while minimising complications and cost, prospective
randomised studies comparing PMT vs conventional
treatment should be performed. Patients should be followed
for at least two years to detect valve insufficiency and
signs and symptoms of PTS. 
C O N C L U S I O N
It is difficult to draw definitive conclusions based on the
published data on thrombolysis, since studies have
included relatively small numbers of patients, a range of
thrombolytic regimens, and varying durations of follow-up.
Furthermore, outcomes, including the degree of clot lysis
and the incidence of the PTS, have been assessed using a
range of modalities.
When compared with anticoagulation, thrombolytic therapy
for DVT leads to superior short-term venous patency and
a higher risk of major haemorrhage but no difference in
the rates of PE and mortality. 
It is not clear how many patients with DVT are actually
candidates for thrombolytic therapy. 
One study, for example, found that 194 out of 209
patients (93%) had a contraindication for thrombolysis,
most often recent surgery.52 Elshawary et al. also included
only 35 out of 207 patients.43
Based on this review, there is no advantage in using any
thrombolytic agent over another, or using local vs systemic
administration. There is a need to further evaluate CDT
and PMT. CDT instils the thrombolytic agent directly into
the thrombus and can be combined with mechanical
removal of thrombus using a suction catheter or stenting
of a residual clot. This type of therapy has been suggested
as an alternative to standard therapy based on a better
lysis rate of 60 to 80%. Unfortunately, because these rates
are derived from case series and patient registry data,
they are susceptible to selection or reporting bias and the
true benefit may be lower. Furthermore, the bleeding rate
with this therapy is considerably higher than rates with
conventional therapy, even with this select population. It
should be noted that, although CDT and PMT techniques
offer advantages of allowing faster and more complete
clot clearance, which translate into remarkably faster
symptom resolution, to date there have been no ran-
domised trials comparing this form of therapy with con-
ventional anticoagulation in terms of prevention of PTS.
Until such trials are conducted or more clinical experi-
ence suggests the superiority of these evolving treatment
modalities in acute DVT, it is important to continue to
restrict aggressive endovascular interventions to situations
in which compelling indications exist (table 5).
With respect to the patient characteristics, we need to know
which patients benefit most from aggressive therapy.
Perhaps the younger, healthier patient, who will face many
years of decreased productivity if severe PTS develops, is
the main candidate. In addition, young, healthy patients
possibly have a decreased risk of bleeding related to
thrombolysis. 
Future research using randomised controlled studies
should focus on the following key questions:
- Does thromboablative therapy improve long-term out-
comes of DVT with a favourable risk-to-benefit ratio
and, if so, which patients are most likely to benefit in
the long term?
- What is the precise role of CDT or PMT in the treatment
of VTE, particularly the use of a low-dose thrombolytic
agent in conjunction with mechanical clot disruption
to minimise bleeding in patients with high risk? 
Janssen, et al. Local and systemic thrombolytic therapy.
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Table 4
Percutaneous mechanical thrombectomy for DVT
AUTHOR N MEAN DEVICE THROMBO- SIGNIFICANT/ PE STENT MAJOR DEATH PTS
(YEAR) FOLLOW-UP LYTIC RESOLUTION BLEEDING
(MONTHS) N N (%) N (%)
Kasirajan 17 9 Angiojet 9 10 (59) 0 7 0 0 ND
(2001)
Delomez* 18 29.6 Amplatz/- 0 15 (83) 0 6 0 1 1
(2001)
Vedantham 28 ** 28 UK/ 17 (62) 0 18 3 (14) 0 ND
(2002) rt-PA
Vedantham 23 19.8 Helix 23 19 (83) 0 23 1 (6) 0 2 
(2004) reteplase
PE = pulmonary embolism; PTS = post-thrombotic syndrome; UK = urokinase; rt-PA = recombinant plasminogen activator; ND = not determined; 
*only mechanical treatment after failure of conventional heparin after 48 hours + cava filter, **different devices were used: Amplatz, Angiojet, Trerotola and Oasis.
According to the current data, thrombolytic treatment
for DVT should not be applied except in extraordinary
circumstances. First, the long-term effectiveness in terms
of reducing PTS, although possible, remains uncertain.
Second, the risks of thrombolytic therapy are high. Third,
current conventional therapy is relatively inexpensive,
convenient and safe.
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Possible indications for interventional therapy on acute
lower extremity DVT
Young or highly functional patients with iliofemoral DVT
Extensive thrombus burden
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Associated findings of venous ischaemia
Phlegmasia cerulea dolens
High risk of fatal PE
Symptomatic IVC thrombosis after filter placement
Propagation of DVT despite conventional therapy
High likelihood of underlying anatomic abnormality (previous pelvic
DVT, compression by pelvic tumour, May-Thurner syndrome)
31. Goldhaber SZ, Polak JF, Feldstein ML, Meyerovitz MF, Creager MA.
Efficacy and safety of repeated boluses of urokinase in the treatment of
deep venous thrombosis. Am J Cardiol 1994;73:75-9.
32. Jeffrey P, Immelman EJ, Amoore J. Treatment of deep vein thrombosis
with heparin or streptokinase: long-term venous function assessment
[Abstract]. Proc Sec Int Vasc Symp London 1986.
33. Kakkar VV, Flanc C, Howe CT, O’Shea M, Flute PT. Treatment of deep
vein thrombosis. A trial of heparin, streptokinase, and arvin. BMJ
1969;1:806-10.
34. Marder VJ, Soulen RL, Atichartakarn V. Quantitative venographic assessment
of deep vein thrombosis in the evaluation of streptokinase and heparin
treatment. J Lab Clin Med 1977;89:1018-29.
35. Porter JM, Seaman AJ, Common HH, Rosch J, Eidemiller LR, 
Calhoun AD. Comparison of heparin and streptokinase in the treatment
of venous thrombosis. Am Surg 1975;41:511-9.
36. Robertson B, Nilsson IM, Nylander G. Value of streptokinase and
heparin in treatment of acute deep vein thrombosis. Acta Chir Scand
1968;134:203-8.
37. Robertson B, Nilsson IM, Nylander G. Thrombolytic effect of streptokinase
as evaluated by phlebograhy of deep venous thrombi of the leg. Acta Chir
Scand 1970;136:173-80.
38. Schulman S, Granqvist S, Juhlin-Dannfelt A. Long-term sequelae of calf
vein thrombosis treated with heparin of low-dose streptokinase. Acta
Med Scand 1986;219:349-57.
39. Schweizer J, Kirch W, Koch R, et al. Short- and long-term results after
thrombolytic treatment of deep venous thrombosis. J Am Coll Cardiol
2000;36:1336-43.
40. Tsapogas MJ, Peabody RA, Wu KT. Controlled study of thrombolytic therapy
in deep vein thrombosis. Surgery 1973;74:973-84.
41. Turpie AG, Levine MN, Hirsh J, Ginsberg JS, Cruickshank M, Jay R.
Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis:
results of a randomized trial. Chest 1990;97:S172-5.
42. Watz R, Savidge GF. Rapid thrombolysis and preservation of valvular venous
function in high deep vein thrombosis. Acta Med Scand 1979;205:293-8.
43. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation
in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc
Endovasc Surg 2002;24:209-14.
44. Arnesen H, Hoiseth A, Ly B. Streptokinase of heparin in the treatment of
deep vein thrombosis. Follow-up results of a prospective study. Acta Med
Scand 1982;211:65-8.
45. Bieger R, Boekhout-Mussert RJ, Hohmann F, Loeliger EA. Is streptokinase
useful in the treatment of deep vein thrombosis? Acta Med Scand
1976;199:81-8.
46. Common HH, Seaman AJ, Rosch J, Porter JM, Dotter CT. Deep vein
thrombosis treated with streptokinase or heparin. Follow-up of a randomized
study. Angiology 1976;27:645-54.
47. Johansson L, Nylander G, Hedner U, Nilsson IM. Comparison of strepto-
kinase with heparin: late results in the treatment of deep venous
thrombosis. Acta Med Scand 1979;206:93-8.
48. Kakkar VV, Howe CT, Laws JW, Flanc C. Late results of treatment of deep
vein thrombosis. BMJ 1969;1:810-1.
49. Theiss W, Wirtzfeld A, Fink U, Maubach P. The success rate of fibrinolytic
therapy in fresh and old thrombosis of the iliac and femoral veins.
Angiology 1983;34:61-9.
50. Schweizer J, Nierade A, Florek HJ, Altmann E. Ultrasound angiography
in diagnosis of deep venous thrombosis and post-thrombotic syndrome.
A prospective comparative study. Ultraschall Med 1997;18:88-90.
51. Hirsh J, Lensing AW. Thrombolytic therapy for deep vein thrombosis. Int
Angiol 1996;5:S22-5.
52. Markel A, Manzo RA, Strandness DE Jr. The potential role of thrombolytic
therapy in venous thrombosis. Arch Intern Med 1992;152:1265-7.
53. Grossman C, McPherson S. Safety and efficacy of catheter-directed thrombo-
lysis for iliofemoral venous thrombosis. Am J Roentgenol 1999;172:667-72.
54. Baldwin ZK, Comerota AJ, Schwartz LB. Catheter-directed thrombolysis
for deep venous thrombosis. Vasc Endovasc Surg 2004;38:1-9.
55. Burkart DJ, Borsa JJ, Anthony JP, Thurlo SR. Thrombolysis of occluded
peripheral arteries and veins with tenecteplase: a pilot study. J Vasc Interv
Radiol 2002;13:1099-102.
56. Castaneda F, Li R, Young K, Swischuk JL, Smouse B, Brady T. Catheter-
directed thrombolysis in deep venous thrombosis with use of reteplase:
immediate results and complications from a pilot study. J Vasc Interv
Radiol 2002;13:577-80.
57. Cho YP, Jang HJ, Lee DH, et al. Deep venous thrombosis associated with
protein C and/or S deficiency: management with catheter-directed
thrombolysis. Br J Radiol 2003;76:380-4.
58. Comerota AJ, Kagan SA. Catheter-directed thrombolysis for the treatment
of acute iliofemoral deep venous thrombosis. Phlebology 2000;15:149-55.
59. Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase, and
reteplase for catheter-directed thrombolysis of deep venous thrombosis.
J Vasc Interv Radiol 2004;15:347-52.
60. Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N,
Haughton SH. Catheter-directed thrombolysis for lower extremity deep
venous thrombosis: report of a national multicenter registry. Radiology
1999;211:39-49.
61. Palombo D, Porta C, Brustia P, et al. Loco-regional thrombolysis in deep
venous thrombosis. Phlebologie 1993;46:293-302.
62. Raju S, Fountain T, McPherson SH. Catheter-directed thrombolysis for
deep venous thrombosis. J Miss State Med Assoc 1998;39:81-4.
63. Semba CP, Dake MD. Catheter-directed thrombolysis for iliofemoral
venous thrombosis. Semin Vasc Surg 1996;9:26-33.
64. AbuRahma AF, Perkins SE, Wulu JT, Ng HK. Iliofemoral deep vein
thrombosis: conventional therapy versus lysis and percutaneous trans-
luminal angioplasty and stenting. Ann Surg 2001;233:752-60.
65. Bjarnason H, Kruse JR, Asinger DA, et al. Iliofemoral deep venous
thrombosis: safety and efficacy outcome during 5 years of catheter-directed
thrombolytic therapy. J Vasc Interv Radiol 1997;8:405-18.
66. Emanuelli G, Segramora V, Frigerio C. Selected strategies in venous
thromboembolism: local thrombolytic treatment and caval filters.
Haematologica 1995;80:84-6.
67. Horne MK, III, Mayo DJ, Cannon RO, III, Chen CC, Shawker TH, Chang
R. Intraclot recombinant tissue plasminogen activator in the treatment of
deep venous thrombosis of the lower and upper extremities. Am J Med
2000;108:251-5.
68. Molina JE, Hunter DW, Yedlicka JW. Thrombolytic therapy for iliofemoral
venous thrombosis. Vasc Surg 1992;26:630-7.
69. Verhaeghe R, Stockx L, Lacroix H, Vermylen J, Baert AL. Catheter-directed
lysis of iliofemoral vein thrombosis with use of rt-PA. Eur Radiol
1997;7:996-1001.
Janssen, et al. Local and systemic thrombolytic therapy.
M A R C H  2 0 0 5 ,  V O L .  6 3 ,  N O .  3
89
70. Meissner MH. Thrombolytic therapy for acute deep vein thrombosis and
the venous registry. Rev Cardiovasc Med 2002;3(suppl 2):S53-60.
71. Comerota AJ. Quality-of-life improvement using thrombolytic therapy
for iliofemoral deep venous thrombosis. Rev Cardiovasc Med
2002;3(suppl 2):S61-7.
72. Elliott G. Thrombolytic therapy for venous thromboembolism. Curr Opin
Hematol 1999;6:304-8.
73. Ouriel K, Gray B, Clair DG, Olin J. Complications associated with the use
of urokinase and recombinant tissue plasminogen activator for catheter-
directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol
2000;11:295-8.
74. Sharafuddin MJ, Sun S, Hoballah JJ, Youness FM, Sharp WJ, Roh BS.
Endovascular management of venous thrombotic and occlusive diseases
of the lower extremities. J Vasc Interv Radiol 2003;14:405-23.
75. Morgan R, Belli AM. Percutaneous thrombectomy: a review. Eur Radiol
2002;12:205-17.
76. Frisoli JK, Sze D. Mechanical thrombectomy for the treatment of lower
extremity deep vein thrombosis. Tech Vasc Interv Radiol 2003;6:49-52.
77. Vedantham S, Vesely TM, Parti N, Darcy M, Hovsepian DM, Picus D.
Lower extremity venous thrombolysis with adjunctive mechanical
thrombectomy. J Vasc Interv Radiol 2002;13:1001-8.
78. Delomez M, Beregi JP, Willoteaux S, et al. Mechanical thrombectomy in
patients with deep venous thrombosis. Cardiovasc Intervent Radiol
2001;24:42-8.
79. Kasirajan K, Gray B, Ouriel K. Percutaneous AngioJet thrombectomy in
the management of extensive deep venous thrombosis. J Vasc Interv
Radiol 2001;12:179-85.
80. Vedantham S, Vesely TM, Sicard GA, et al. Pharmacomechanical
thrombolysis and early stent placement for iliofemoral deep vein throm-
bosis. J Vasc Interv Radiol 2004;15:565-74.
81. McLennan G, Trerotola SO, Davidson D, et al. The effects of a mechanical
thrombolytic device on normal canine vein valves. J Vasc Interv Radiol
2001;12:89-94.
82. Trerotola SO, McLennan G, Davidson D, et al. Preclinical in vivo testing
of the Arrow-Trerotola percutaneous thrombolytic device for venous
thrombosis. J Vasc Interv Radiol 2001;12:95-103.
M A R C H  2 0 0 5 ,  V O L .  6 3 ,  N O .  3
Janssen, et al. Local and systemic thrombolytic therapy.
90
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Richtlijn Behandeling van tabaksverslaving
Met jaarlijks meer dan 20.000 doden door
tabaksgebruik, is roken in Nederland een
volksgezondheidsprobleem van de eerste
orde. Dertig procent van de bevolking rookt
nog. De winst van stoppen met roken is niet
alleen voor de maatschappij als geheel, maar
ook voor elke individuele roker, aanzienlijk.
De meeste rokers blijken graag te willen
stoppen. Velen hechten daarbij grote waarde
aan advies van een medicus. 
De richtlijn sluit aan op het principe van een-
malige en korte ondersteunende interventies
en op het model van ‘stages of change’. De
minimale-interventiestrategie (MIS) kent in
ons land als toegepaste methode een zekere
traditie waar het gaat om het bieden van
‘stoppen met roken’-adviezen: diverse beschik-
bare programma’s zijn hierop gebaseerd. In
de richtlijn wordt de MIS echter als een
methode gezien en wordt een andere indeling
gehanteerd dan in de traditie van de MIS.
Een belangrijk uitgangspunt in richtlijnen
voor de medische praktijk is dat optimaal
gebruik wordt gemaakt van beschikbare voor-
zieningen. In deze richtlijn is dat ook het geval
waar het gaat om een consistente motiverende
interventie bij rokers. Een bijzonder punt in
deze richtlijn is echter het positioneren van
gespecialiseerde voorzieningen. Deze, in het
Verenigd Koninkrijk en de Verenigde Staten
bekende, voorzieningen zijn in ons land op
beperkte schaal voorhanden. Met het lanceren
van deze richtlijn wordt bepleit dat zulke
faciliteiten op grotere schaal beschikbaar
komen. Ondanks het beperkte wetenschap-
pelijk bewijs wordt hiervoor een argumentatie
gegeven. Daarmee zal het realiseren van de
inspanning om via individuele interventies
het tabaksgebruik terug te dringen, aan
slagkracht winnen.
In de gezondheidszorg doen zich op grote
schaal contacten met individuele rokers voor.
In deze richtlijn worden die momenten als
aanleiding beschouwd om stoppen met roken
aan de orde te stellen. Voor de medische
praktijk en de daarbij betrokken hulpverleners
biedt deze richtlijn mogelijkheden om tabaks-
verslaving effectief te behandelen. Hoewel
primaire preventie met name voor jongeren
van groot belang is, komt in deze richtlijn
alleen de behandeling van tabaksverslaving
in de zorg aan de orde.
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I N T R O D U C T I O N
Falls are common in the elderly and contribute to morbidity
and mortality. Elderly people are often on a variety of
medications as well, and this suggests a causative relation
between use of medicine and falls. However, the evidence
available to support this assumed relationship is not very
robust. In this article, we will discuss specifically the
medications that are presumed to be associated with falls.
Falls in older people are a major public health problem
with significant consequences for individuals, their families,
and healthcare providers. The incidence of hip fractures
increases with age. In the over 65 year olds, the rate of
hospital admissions due to fractures from falls is
increasing.1 There has been a doubling of the hospital
admission rate for patients >65 years with a hip fracture
in the Netherlands during the last 20 years.2-4 This has
resulted in an enormous increase in the costs of intramural
and extramural healthcare. In addition to an influence on
morbidity and mortality, falls have a negative effect on
daily life activities and quality of life. This is especially so
when the fear of falling leads to avoidance behaviour,
which promotes inactivity with a further deconditioning
of musculoskeletal function, propensity to inactivity and
social isolation, all facilitating new falls.5
In the elderly, falls represent a multifactorial problem
which should be regarded as the result of complex inter-
actions between intrinsic factors and factors relating to
environment and the specific situation. Judicious application
of medications that enhance the likelihood of falling
probably contributes to prevention of an important cause
of morbidity in the elderly.6 Recent data from the Dutch
Foundation for Pharmaceutical Statistics (SFK) have
revealed that salicylates used as an antiplatelet agent,
temazepam, furosemide and oxazepam (also see:
www.sfk.nl) are among the medicines most frequently
taken by elderly patients (>65 years).
Pathophysiology of orthostatic hypotension is discussed and
changes in the pharmacokinetics and pharmocodynamics
due to ageing are addressed. A focus will be on the evidence
currently available on medication as a risk factor for the
occurrence of dizziness and falls. Osteoporosis and
effects of medications on reaction time are beyond the
scope of this review.
D E F I N I N G  T H E  P R O B L E M
For elderly people aged >65 years who live in the community,
the risk of falling varies from 25 to 40% a year,2,3,7,8 while
for the institutionalised elderly this can be as high as
70%.9 The incidence of falls increases with age and is
greater in women.10-12
At least 5% of community-dwelling elderly >65 years will
suffer from a fracture related to a fall. Especially fractures
of the hip result in hospital admission4 with a death rate
within the following year of 20 to 30%.13,15 The same per-
centage of elderly people is admitted to a nursing home
because of remaining disability.13,14
P A T H O P H Y S I O L O G Y  O F  O R T H O S T A S I S
Normovolaemia may be defined as the effectively circulating
volume of a healthy person in the supine position.17 A
change in posture to the upright position elicits a shift of
© 2005 Van Zuiden Communications B.V. All rights reserved.
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~300 to 800 ml of blood from the chest to the lower parts
of the body. To maintain cardiac output, the consequent
fall in ventricular filling volume must be met by continuous
adjustment of arterial and venomotor tone and by regulating
cardiac contractility and chronotropy.18 Humans can stand
upright for long periods of time. Their orthostatic circulatory
adaptation is provided by the evolution of an effective set
of neuromuscular and circulatory mechanisms that are
largely involuntary or autonomic, aiming to preserve
arterial pressure as the controlled variable, independent
of gravity. The arterial baroreflex is the well-known example
of short-term control acting within the single heartbeat,
while the more slowly acting but extremely powerful
humoral-cardiovascular-renal system secures body fluid
control, provided the fluid intake is normal.19,20
Orthostatic stress affects cerebral perfusion pressure
and the cerebral autoregulatory system aims to limit the
postural reduction in perfusion of the brain. Nevertheless
assumption of the sitting or standing position affects
cerebral perfusion and regional cerebral oxygenation in
healthy humans.21-23
Age-related changes
Although function and efficacy of cardiovascular reflex
activity change with increasing age,24,25 arterial pressure
in the upright position is usually well maintained.26 In
addition, the magnitude of the blood volume declines with
age but its possibly disadvantageous effects are offset at
least in part by the concurrent decline in venous compliance
limiting the volume of blood pooled. This explains the
increased susceptibility of elderly patients for diuretic
treatment interfering with the maintenance of blood
volume and thus orthostatic tolerance.27,28
Postural stress affects cerebral oxygenation in the elderly29
but it is as yet uncertain whether this is related to a
decline in autoregulatory capacity.30 Orthostatic tolerance in
the elderly is reduced,31 and blood pressure and cerebral
perfusion are affected further for at least for ~45 to 60
minutes following a meal.32-36 Postprandial hypotension is
defined as a >20 mmHg postural drop in systolic blood
pressure but this cut-off point should be regarded as less
relevant with respect to the development of orthostatic
symptoms.16 Especially in elderly people with hypertension
a limited reduction in blood pressure may already elicit
symptoms of cerebral incompetence.37 Following a meal,
instead of resting, walking may benefit postprandial
blood pressure and development of symptoms.38
Moderate exercise training expands plasma volume and
enhances leg muscle tone limiting orthostatic venous
pooling and supporting orthostatic tolerance.39 In the
elderly the use of medicines and time of a meal may
interfere with orthostatic tolerance in a complex way.
A G E - R E L AT E D  C H A N G E S  O F  P H A R M A C O -
K I N E T I C S  A N D  P H A R M A C O D Y N A M I C S
In the elderly, the rate of absorption of most drugs
administered orally is almost identical to that of younger
people, but with ageing marked changes in body compon-
ents affect the distribution. Body fat as a proportion of
body weight increases by over 35% from the age of 20 to
70 years. There is a concurrent decrease in plasma volume
of 8% with normal ageing; lean body mass and total body
water decrease approximately 17%40 with an increased rate
of adverse effects of both lipophilic (for example diazepam:
large volume of distribution) and hydrophilic medications
(high plasma concentration). Also the metabolism of many
medicines changes with ageing. Hepatic biotransformation
is a prerequisite for drugs with limited renal clearance.
There is a modest decrease in the efficiency of phase I
reactions (oxidative and hydroxylation processes), reactions
generally mediated by the mixed-function monooxygenase
system (cytochrome P-450 system). In contrast, phase II
reactions (by conjugation enzymes and transferases) are
generally unaffected and in older vs younger patients drugs
metabolised by phase II processes only are preferable.
Drugs known to have a strong ‘first pass’ effect, such as
metoclopramide and opiates, should be used in low doses.
Renal drug excretion includes glomerular filtration, tubular
secretion, and in a varying degree, tubular reabsorption as
well. The half-life of a drug is directly related to the volume
of distribution and inversely related to its clearance (metab-
olism and excretion). In the majority of elderly people renal
function is diminished due to a reduction in both renal blood
flow and number of functional nephrons with an increased
half-life for drugs that depend on renal function for elim-
ination.41 Insight into the effects of ageing on pharmaco-
dynamics, probably through disease-related changes in
target organs, diminished reserve capacity and changes in
receptor function of end organs, is limited.42 As an example,
the plasma concentration of diazepam required to achieve
a certain level of sedation is much lower in the elderly than
in subjects aged 30 to 50 years. An increased sensitivity has
also been shown for opiates, anticholinergic and antihyper-
tensive drugs and dopamine agonists. In contrast, the
susceptibility of older vs younger patients for -blockade and
insulin40 is reduced. From this viewpoint, data from litera-
ture concerning antipsychotics, (tri)cyclic antidepressants,
anticonvulsive and cardiovascular medications are discussed. 
M E D I C A L  C A U S E S  A N D  R I S K  F A C T O R S
F O R  D I Z Z I N E S S  A N D  F A L L S
Theoretically, randomised controlled trials are likely to
provide the evidence to prove the causal relationship
between medication use and falls. When addressing the
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specific cause of falls, the rate of falls must be known both
in the intervention and the control group but such evidence
is only rarely available. Data on the relationship between
drugs and falls are usually derived from observational
studies, for instance from cohort or patient-controlled
studies, rendering interpretation of results difficult. 
The majority of studies and reports available suggest a
relationship between number of medications and the risk
of falls.9,40,43-53 Also a recent change in dosage of drugs is
associated with an increased risk of falls. The use of
psychotropic medication is regarded as a risk factor for
falls.40,54,55 Psychoactive medication likely contributes to
the occurrence of falls by affecting balance, partly because
of the extrapyramidal side effects, dizziness and postural
hypotension56 in addition to a delayed reaction time, with
a higher incidence if combinations of medications are
used. A fall resulting in hospital admission in the elderly
is likely to be regarded as a side effect of drug treatment.57
The risk of falls in the elderly is increased with postural
instability, regardless of the cause which can range from
acute illness with fever and dehydration, the use of a
specific drug affecting plasma volume or the reaction
time to floor covering. The risk of a second fall within
one year is increased especially in elderly individuals on
benzodiazepines, neuroleptics or anticonvulsants.58
Tables 1 and 2 give the odds ratios of psychoactive agents
and falls. 
P R O B L E M S  C O N C E R N I N G  R E S E A R C H
O F  F A L L S  A N D  M E D I C A T I O N S
The available data from studies on risks of falls are difficult
to compare because of the different definitions used for
falls, the nature of the analysed risks, and the populations
interrogated. Confounding by indication remains a most
important consideration in pharmacoepidemiology. 
Polypharmacy in the elderly is associated with an increased
risk of falling, but it is equally likely to result from physical
and mental frailty.40,52,59,60 When interpreting epidemiological
data it should be considered that in the majority of studies
subjects in poor health were excluded from analysis, with
gross underestimation of adverse drug events. In addition,
the design of many studies focussed primarily on risk
factors rather than on drugs.40 Lumping together several
groups of medications (excluding all psychoactive drugs)
and poor recording of actual medication use at the time
of the fall in many studies has limited the opportunity to
identify specific drug classes. In addition, recall of falls
and sample size to detect a moderate increase in drug
risk is often insufficient, a methodological error common
to many studies addressing adverse events of drugs.
Neuroleptics
All classes of neuroleptics increase the risk of falling, but
through different mechanisms, including enhancement of
extrapyramidal disturbance, syncope, -blockade, sedation,
postural hypotension and/or cognitive impairment.61-63
Tricyclic antidepressants and selective serotonin reuptake
inhibitors
A prerequisite for appropriately identifying falls as
adverse events from the use of tricyclic antidepressants
(TCAs) and selective serotonin reuptake inhibitors (SSRIs)
is that a distinction is made between studies conducted in
normal volunteers and those with symptoms of depression.
When comparing drugs, the risk of falling relates to the
sedative characteristics of the drug used. The risk of con-
tracting a fractured hip is increased in elderly patients on
tricyclic antidepressants, probably related both to the drug
itself and to depression or confusion.47 Confounding by
indication can be of influence on the results of studies. In
a recent study that corrected for indication by indication,
an influence of prescription was no longer detected.58
In elderly patients on antidepressants, sedation with
psychomotor retardation has been proposed as the most
likely cause of falls.64 When using TCAs, orthostatic
hypotension (as a result of -blockade) and cardiac
arrhythmias are the most important factors contributing
to falls. When using SSRIs, the risk is comparable65-68 or
even larger58 than the risk with TCAs.
Daal, et al. Falls and medications in the elderly.
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Table 1
Pooled OR for associations between use of various psycho-
tropic medications from 40 nonrandomised controlled
trial46,63
Benzodiazepines OR 1.48 (95% CI 1.23-1.77)
Short-acting OR 1.44 (95% CI 1.09-1.90)
Long-acting OR 1.32 (95% CI 0.98-1.77)
Antidepressants OR 1.66 (95% CI 1.38-2.00)
TCAs OR 1.51 (95% CI 1.14-2.00)
SSRIs: low dose OR 1.50 (95% CI 1.30-1.70)
high dose OR 2.40 (95% CI 1.70-2.20)
Neuroleptics OR 1.50 (95% CI 1.25-1.79)
OR = odds ratio; TCA = tricyclic antidepressant; SSRI = selective serotonin
reuptake inhibitor.
Table 2
Psychotropic medication from nonrandomised controlled
trials46,63
Benzodiazepines
Short-acting Lorazepam, oxazepam, temazepam,
alprazolam, triazolam, bromazepam
Long-acting Flurazepam, chlordiazepoxide, clonazepam,
clorazepate, diazepam, prazepam
Antidepressants Tricyclic antidepressants, selective serotonin 
reuptake inhibitors
Neuroleptics Phenothiazines, butyrofenones
Polypharmacy in the elderly enhances the chance of inter-
action between drugs. Some SSRIs are strong inhibitors
of isoforms of the cytochrome P450 system with important
pharmacodynamic interactions.
No pharmacokinetic interaction was reported for
dopamine agonists and SSRIs. On theoretical grounds
interaction between ropinirol and fluvoxamine is likely
because of the inhibition of metabolism of ropinirol
through CYP1A2 by fluvoxamine.62
Benzodiazepines
In normal volunteers, benzodiazepines impair function
in tests of postural sway, they delay reaction time, cause
ataxia, reduce proprioception during the period corres-
ponding to the drug’s elimination half-life69,40 but for the
elderly the results are less uniform. Although in most
studies a correlation between long half-life time and falls
is confirmed, there is also evidence that benzodiazepines
with a short half-life also lead to an increased risk of
falls.58,70 In one study the dose was more important than
the half-life as such.71 In elderly patients in general, side
effects are more serious for each dose, regardless of the
dosage, due to the mentioned changes in pharmocokinetics
and pharmacodynamics.72
Anticonvulsants 
The following side effects of anticonvulsants may be related
to falls: sedation, dizziness and balance disturbances. In
one study the likelihood of falling (≥1) for women taking
anticonvulsants vs controls almost doubled, as did the
rate of falling.58
Cardiovascular drugs 
A relationship between usage of antihypertensive agents,
diuretics or nitrates and the occurrence of falls in the
elderly may seem plausible but it is hard to prove. In a
meta-analysis of 29 nonrandomised studies addressing
the relationship between cardiovascular drugs and falls in
the elderly, a weak relationship could only be found for
digitalis, type 1A antiarrhythmetic drugs and diuretics. 
The evidence was, however, weak and based merely on
observations with minimal correction for confounders,
dosage or duration of treatment.45 From a practical view-
point, in the absence of firm evidence it is worthwhile to
reconsider diuretic treatment in the elderly73 although in a
meta-analysis of randomised, cohort and patient-controlled
studies no clear causal relationship between diuretic
treatment and falls could be identified.74 Polypharmacy is
common and this is especially so in cardiovascular disease
with chronic heart failure as an example, involving com-
bination treatment with ACE inhibition, -adrenergic
blocking agents and often diuretics as well. The occurrence
of orthostatic hypotension is a side effect of treatment
aiming at left ventricular afterload reduction.
Nevertheless a meta-analysis of 15 randomised trials
regarding antihypertensive treatment in >21,000 subjects
>60 years of age for at least a year did not reveal an
increased fall rate.75
I N T E R V E N T I O N S
Reduction in total number of medications
When starting a drug or changing its dosage, one must
decide whether it is clearly indicated and also if the bene-
fits of the prescribed drug counterbalance its possible
adverse effects, especially in the case of benzodiazepines,
neuroleptics, antidepressants, anticonvulsants and cardio-
vascular medications. If a drug is indicated, it may be an
option to choose a drug from a different class. In addition,
in the elderly, periodical evaluation of the indications for
drug treatment and/or consideration of dosage reduction
is warranted. The ultimate goal is to optimalise daily
functioning with a maximum of profit from drug treatment
and a minimum of adverse effects, such as falls. In a single
randomised double-blind trial addressing stopping of
psychotropic drug treatment in institutionalised elderly
patients >80 years, the risk of falling was reduced by
66%.50 Reducing the total number (to less than four) of
medications is a real option to reduce the risk of
falls.6,54,76,77
Information and advice
When prescribing and delivering drugs it is important to
inform the patient on the use of medication and their
role in signalling side effects. The patient also has a
responsibility concerning self-medication and reporting
adverse events allowing timely intervention in limiting
adverse events and interactions.
P E R S P E C T I V E
The relation between usage of drugs and falls has been
studied in many trials, but the majority are retrospective,
uncontrolled trials. From the data of studies available it is
not yet possible to reveal a causal relationship for most
drugs. Data from the majority of trials suggest that the use
of drugs involves an increased risk of falling, especially in
the frail geriatric patient on several drugs.
When prescribing a new medication in the older patient,
the indication should be considered critically without with-
holding of treatment. When a decision to start treatment
is made, one should ‘start low, go slow’, with explicit
attention and active search to possible adverse events.
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A B S T R A C T
Background: Hypothyroidism is regarded as a risk factor
for coronary artery disease. Possible factors involved in
this association are hyperlipidaemia and hypertension,
both occurring with increased frequency in hypothyroid
patients. The aim of our study was to evaluate
signs/symptoms of cardiac ischaemia in untreated
hypothyroid patients without angina pectoris, since this
has never been performed before. 
Methods: 51 consecutive cardiac asymptomatic patients
(mean age 47, range 22 to 86 years) were studied by
dobutamine stress echocardiography and bicycle 
ergometry. 
Results: Mean values of body mass index, resting heart
rate and blood pressure were 28.5 kg/m2, 68 beats/min
and 129/81 mmHg, respectively. Median TSH was 51.9
mU/l, mean FT4 7.3 ± 2.9 pmol/l (mean ± SD), TT3 1.6 ±
0.6 nmol/l and total cholesterol was 5.8 ± 1.6 mmol/l.
None of the patients had symptoms of angina pectoris
during dobutamine stress echocardiography or bicycle
ergometry and no evidence of myocardial ischaemia was
demonstrated. Exercise tolerance, assessed by dividing the
maximum achieved workload by the target performance
(depending on body height, sex and age), was diminished
in 38% of patients, and significantly related to the degree
of hypothyroidism. 
Conclusion: No angina pectoris or cardiac ischaemia at
exercise or stress was found in cardiac asymptomatic
hypothyroid patients. The precise role of hypothyroidism
as a risk factor for coronary artery disease should be
further elucidated.
I N T R O D U C T I O N
Hypothyroidism and cardiac diseases have been associated
for almost a century now. In 1918, Zondek introduced the
term ‘myxoedema heart’, referring to pericardial effusion,
ventricular dilatation and hypertrophy, and interstitial
oedema with swelling of myocardial fibres.1 In 1924, a
first case of angina pectoris associated with myxoedema
was reported.2 Subsequently, several authors warned of
the danger of initiating or aggravating angina pectoris, or
even precipitating acute myocardial infarction, during
thyroid replacement therapy in patients with both
hypothyroidism and coronary artery disease.3-6 Moreover,
autopsies performed in hypothyroid patients before or
during thyroid hormone therapy demonstrated coronary
atherosclerosis and even fresh coronary occlusion.3,6-8
Independently of age, sex and associated disorders,
hypothyroidism was found to favour the development of
coronary artery atherosclerosis.7,8
Several mechanisms might be involved in this historical
association of hypothyroidism with ischaemic heart disease.
Since both abnormalities of lipid metabolism (increased
serum total cholesterol and low density lipoprotein chol-
esterol) and arterial hypertension occur with increased
frequency in hypothyroidism, those two factors are
regarded as possible causal factors.9-15 Furthermore, it has
been suggested that pathological immune reactivity in
autoimmune thyroiditis, a common cause of thyroid failure,
may be important in the above-referenced association.16
As a consequence, most physicians are still hesitant
about initiating the treatment of hypothyroid patients
with a full dosage of thyroxine, even though Singer et al.
suggest starting with a full replacement dosage of
levothyroxine in those under the age of 50 without known
© 2005 Van Zuiden Communications B.V. All rights reserved.
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cardiac disease.17 A systematic prospective study examining
the prevalence of cardiac ischaemia before and during
treatment, however, has never been performed. Most of
the published studies on the association of hypothyroidism
with coronary artery disease were retrospective, based
only on the patient’s history without the application of
diagnostic tests, the numbers of the patients studied were
often small and, particularly in earlier studies, patients
were treated with desiccated thyroid containing differing
amounts of triiodothyroxine. 
The prevalence of coronary artery disease in untreated
hypothyroid patients needs to be known to be able to
determine the risk of angina pectoris developing during
thyroid replacement therapy. By excluding patients with a
known history of cardiac disease we were able to study only
those patients in whom the development of angina pectoris
due to coronary artery disease would be unexpected. 
We therefore conducted a prospective study in which we
determined the prevalence of cardiac ischaemia in
untreated hypothyroid patients without symptoms of
angina pectoris. 
M E T H O D S
Study population
All hypothyroid patients who presented to our hospital
between September 1999 and August 2002 were
screened for inclusion. Of these patients, only those with
longstanding primary autoimmune hypothyroidism
(TSH>4.2 mU/l and FT4<10 pmol/l) were included; the
exact duration of hypothyroidism was, therefore,
unknown. Subjects with a history of cardiac disease or
taking cardiac medication were excluded from our study
in order to evaluate the prevalence of ischaemia in
asymptomatic patients and to avoid interference of the
cardiac test results by the use of -blockers and other
cardiac medication. In total, we studied 51 consecutive
patients with untreated hypothyroidism.
At diagnosis, before thyroid hormone replacement therapy
was started, dobutamine stress echocardiography and
bicycle ergometry were performed to identify signs and/or
symptoms of myocardial ischaemia. In addition, an electro-
cardiogram was acquired, body height and weight were
measured for calculation of body mass index (BMI, kg/m2),
blood pressure was measured in a supine position and
free thyroxine (FT4), total triiodothyroxine (TT3), thyroid
stimulatory hormone (TSH), total cholesterol and choles-
terol subfractions and creatine phosphokinase (CK) were
assayed at that time.
Clinical and biochemical characteristics of the study popu-
lation were compared with those of 35 euthyroid, healthy
control subjects chosen from hospital personnel and their
relatives of comparable age who were not taking medication.
The study protocol was approved by the local medical
ethics committee, and informed consent was obtained
from each subject.
Assays
TSH plasma levels (reference range 0.4-4.2 mU/l),
serum TT3 levels (range 1.3-2.5 nmol/l) and FT4 levels
(range 10-23 pmol/l) were determined in a highly sensitive
chemiluminescent enzyme immunoassay (ACS 180, Bayer
Diagnostics, USA). Total cholesterol (range 2.5-6.5 mmol/l),
cholesterol subfractions (high-density lipoprotein (HDL)
cholesterol range 1.0-1.8 mmol/l, low-density lipoprotein
(LDL) cholesterol 1.5-4.5 mmol/l, triglycerides (TG) 0.0-
2.0 mmol/l) and creatine phosphokinase (CK 11-200 U/l)
were measured with a Hitachi 911 (Japan).
Electrocardiography
All 12-lead electrocardiograms (ECGs) were analysed by
one cardiologist and scored according to previously pub-
lished criteria.18
Dobutamine stress echocardiography
This test was performed as previously described.19
In summary, a rest ECG and a two-dimensional echo-
cardiogram were carried out and intravenous access was
secured. Dobutamine was then administered intravenously
by an infusion pump, starting at 10 g/kg/min for three
minutes, increasing by 10 g/kg/min every three minutes
up to a maximum of 40 g/kg/min. In patients not
achieving 85% of their estimated maximal heart rate
(220 beats/min minus age for men, 200 beats/min
minus age for women), atropine was administered on
top of the maximal dosage of dobutamine, starting with
0.25 mg intravenously and repeated up to a maximum of
1.0 mg. Throughout dobutamine infusion, the ECG was
continuously monitored and recorded at three-minute
intervals. Blood pressure was measured and recorded by
an automatic device every three minutes. Images were
digitised in quad screen to allow later visual analysis of
wall motion. Two experienced independent and blinded
cardiologists analysed the echocardiogram. Myocardial
ischaemia was defined as development of new or worsening
of pre-existing wall motion abnormalities in at least two
segments of the left ventricle.
Bicycle ergometry
A Lode bicycle ergometer was used. Workload was started
at 30 watts with 20-watt increments every minute. A con-
stant pedalling rate of 60 revs per minute was required
and exercise was terminated if the patient was unable to
maintain the requested cycling frequency. The ECG was
continuously monitored and blood pressure was measured
and recorded by an automatic device every two minutes.
Ischaemia was defined as development of ST depression
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of ≥0.1 mV during exercise, according to the criteria
described by Roelandt et al.20
Bicycle ergometry can also be used to assess exercise
tolerance, which could be a parameter of hypothyroid
myopathy. Therefore, at the start a target performance
was assessed for each patient, depending on body height,
age and sex. Exercise tolerance was determined by dividing
the maximum achieved workload per patient by his or her
target performance. An exercise performance of less than
80% of the target performance is considered insufficient.
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Statistical comparisons were performed by means of a
two group unpaired Students t-test. A p value <0.05 was
considered significant.
R E S U L T S
Seventy-four consecutive patients with primary 
hypothyroidism were screened for inclusion, of whom 
23 patients were excluded. Clinical and biochemical 
characteristics of the remaining 51 patients and 35 control
subjects are given in table 1. The resting blood pressure of
the experimental patients was 129/81 ± 17/12 mmHg.
The mean body mass index (BMI) was significantly higher
in hypothyroid patients compared with euthyroid controls
(28.5 ± 4.7 vs 24.1 ( 4.9 kg/m2, p=0.0004), resting heart
rate was lower (68 ± 13 vs 80 ± 9 beats/min, p=0.0001),
HDL cholesterol was lower (1.4 ± 0.4 vs 1.5 ± 0.4 mmol/l,
p<0.05), TG were higher (1.6 ± 1.0 vs 1.2 ± 0.6 mmol/l,
p<0.05) and CK was significantly higher (296 ± 746 vs 72
± 39 U/l, p=0.02). 
Twenty-three patients were excluded: 14 for cardiovascular
reasons, such as a history of cardiac disease (myocardial
infarction: n=4; angina pectoris: n=5) and cardiac medica-
tion for longstanding hypertension (n=5). Other reasons
were unwillingness to participate in the study (n=5),
hypothyroidism due to postpartum thyroiditis (n=2),
pregnancy (n=1) and myxoedema (pre)coma (n=1).
Except for age (included vs excluded patients: 47 ± 17 vs
63 ± 18 years, p<0.001) and mean TSH level (100.8 ±
136.5 vs 51.9 ± 30.4 mU/l, p<0.01), clinical and biochemical
characteristics did not differ significantly between the two
groups.
Electrocardiographic abnormalities were observed in 
24 patients: inversion of the T waves (n=4), ST-segment
depression (n=1), sinus bradycardia (heart rate <60 beats/
min, n=16), prolongation of the Q-T interval corrected for
heart rate (QTc >0.43 msec, n=4) and low P wave, QRS
and T wave amplitudes (n=5). Six of the electrocardiograms
showed two different abnormalities.
Dobutamine stress echocardiography
The echocardiogram at rest showed normal wall motion
and normal left ventricular function in all patients.
During dobutamine and later atropine administration,
none of the patients complained of angina pectoris and
none demonstrated wall motion abnormalities signifying
myocardial ischaemia. This test is not designed for the
evaluation of diastolic function.
Bicycle ergometry
As with dobutamine stress echocardiography, none of the
patients had symptoms of angina pectoris during bicycle
ergometry and no ischaemia was demonstrated. No serious
arrhythmias occurred.
Roos, et al. Evaluation of cardiac ischaemia.
M A R C H  2 0 0 5 ,  V O L .  6 3 ,  N O .  3
99
Table 1
Clinical and biochemical characteristics of the included patients and controls
INCLUDED CONTROLS P VALUE
Number 51 35
Male/female 12/39 4/31
Age (years) 47 ± 17 50 ± 12 NS
BMI (kg/m2) 28.5 ± 4.7 24.1 ± 4.9 0.0004
Heart rate (beats/min) 68 ± 13 80 ± 9 0.0001
TSH (mU/l) 100.8 ± 136.5 2.3 ± 1.1 <0.0001
FT4 (pmol/l) 7.3 ± 2.9 13.2 ± 2.1 <0.0001
TT3 (nmol/l) 1.6 ± 0.6 2.0 ± 0.6 0.002
Total cholesterol (mmol/l) 5.8 ± 1.6 5.7 ± 1.0 NS
HDL cholesterol (mmol/l) 1.4 ± 0.4 1.5 ± 0.4 <0.05
LDL cholesterol (mmol/l) 3.7 ± 1.5 3.8 ± 1.1 NS
Triglycerides (mmol/l) 1.6 ± 1.0 1.2 ± 0.6 <0.05
CK (U/l) 296 ± 746 72.3 ± 38.7 0.02
Data as mean ± SD.
Exercise tolerance was insufficient in 38% of patients
(performance of 77 ± 8% of target) and normal in 62% of
patients (performance 110 ± 13% of target). The mean
TSH levels of the patients performing insufficiently were
higher than in those with an exercise performance that
was normal according to body height, sex and age: 154.3
mU/l vs 70.2 mU/l (p<0.05, table 2). FT4 was lower in the
group with reduced exercise tolerance: 6.4 pmol/l vs 7.9
pmol/l (p<0.05). Median CK did not differ significantly
between both groups.
D I S C U S S I O N
Our study clearly showed that no cardiac ischaemia was
demonstrated in 51 consecutive patients with untreated
primary hypothyroidism without previous cardiac symptoms.
Secondly, bicycle ergometry showed that 38% of patients
performed insufficiently, indicating a significant inter-
relationship between exercise performance and degree of
hypothyroidism. This might in part be explained by
impaired cardiac performance with low cardiac output,
caused by bradycardia, a decrease in ventricular filling
and a decrease in cardiac contractility.21,22 Although cardiac
output was not measured in our patients the absence of
impaired left ventricular function makes this a very
improbable explanation. Moreover, heart rate did not differ
significantly between patients with normal or impaired
exercise performance. Another explanation might be the
existence of hypothyroid striated muscle myopathy,23,24
supported by the finding of elevated serum CK in our
patients. However, median CK levels did not differ sig-
nificantly between patients with normal or impaired
exercise performance. Finally, we observed electrocardio-
graphic abnormalities in almost half of the included
patients. It should be stressed, however, that the resting
ECG is not a diagnostic tool for demonstrating cardiac
ischaemia. Electrocardiographic abnormalities that are
frequently observed in patients with hypothyroidism are
sinus bradycardia (heart rate <60 beats/min, 31% of
patients in this study), prolongation of Q-T interval (8% in
this study) and abnormalities associated with pericardial
effusion: flattening or inversion of the T waves (8% in
this study) and low P wave, QRS and T wave amplitudes
(10% in this study).14,15 Obviously, these changes also
occur when pericardial effusion is absent, since none of
our patients had pericardial effusion.
Some possible limitations to our study should be mentioned.
First, the average age of included patients is relatively low.
An explanation for this is that we excluded patients with
cardiac history or symptoms who were relatively older.
However, the included patients did represent all ages
(range 22 to 86 years, median 46 years). Second, bicycle
ergometry may have limited sensibility and specificity for
the presence of coronary artery disease: 55 to 70% and 85
to 95%, respectively,25 with the lowest sensitivity in young
women. However, an advantage of this test is that we
were also able to assess exercise tolerance, something that
has never been done before in untreated hypothyroid
patients. Dobutamine stress echocardiography is the
most specific noninvasive test for assessing coronary
artery disease, with sensitivity and specificity of 80 and
84%, respectively.19 Third, in patients who performed
insufficiently during bicycle ergometry, evaluation of
ischaemia may be suboptimal. However, dobutamine
stress echocardiography with achievement of target heart
rate was performed in these patients and did not show
ischaemia. Finally, the included patients did not have
hypertension and dyslipidaemia. This might be caused by
the fact that nowadays hypothyroidism is often diagnosed
at an early stage due to more frequent testing of serum
TSH.
While in our study no ischaemia was demonstrated, earlier
studies have repeatedly demonstrated the association of
hypothyroidism with coronary artery disease, even in
previously cardiac asymptomatic patients, and of hormone
replacement therapy with angina pectoris.1-9,15,26-27
However, a retrospectively reviewed Mayo Clinic series of
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Table 2
TSH and FT4 in patients with insufficient and normal exercise performance
INSUFFICIENT NORMAL P VALUE
Number 19 31
Male/female 8/11 4/27
Ever smokers 8 8
TSH (mU/l) 154.3 ± 202.6 70.2 ± 58.8 0.047
FT4 (pmol/l) 6.4 ± 3.2 7.9 ± 2.6 0.045
TT3 (nmol/l) 1.3 ± 0.7 1.6 ± 0.5 NS
Systolic BP (mmHg) 124 ± 15 132 ± 17 0.046
Diastolic BP (mmHg) 80 ± 11 80 ± 12 NS
Heart rate (beats/min) 69 ± 11 67 ± 14 NS
Data as mean ± SD.
over 1500 patients with myxoedema shows that angina
pectoris and myocardial infarction are rather infrequent
among hypothyroid patients: just 4% had angina pectoris
before thyroid replacement therapy was started and 2% of
cardiac asymptomatic patients developed angina pectoris
after treatment had begun. Thirty-eight percent of patients
with angina pectoris before initiating thyroid hormone
replacement were even reported to improve.6 This may be
explained by the fact that thyroid hormone replacement
improves myocardial oxygen consumption.28 Most of the
above-mentioned studies on hypothyroidism and coronary
artery disease, however, can be criticised for being either
retrospective or uncontrolled, for small sample sizes or
for using desiccated thyroid containing differing amounts
of levothyroxine and triiodothyroxine. Patients are now
treated by L-T4 only: as this first has to be converted by
the liver into T3 by type I deiodinase, the heart is probably
protected against high elevations of plasma T3 levels. A
systematic consecutive study on this association has
never been reported. 
Interestingly, few studies have been published in which
dobutamine stress echocardiography is performed in
asymptomatic patients with other known risk factors for
coronary artery disease and no studies in hypothyroid
patients have been performed before. We found one
study in which dobutamine stress echocardiography was
performed in asymptomatic diabetic patients having at
least three added risk factors but without rest ECG
abnormalities. The authors concluded that asymptomatic
coronary artery disease is common in diabetes associated
with other risk factors. Moreover, dobutamine stress
echocardiography appeared useful in its detection with a
predictive positive value of 69%.29 We did not find any
studies of cardiac asymptomatic subjects with hyper-
lipidaemia and no studies of dobutamine stress echo-
cardiography in cardiac asymptomatic subjects without
risk factors for coronary artery disease. 
Further research should include a prospective study in
which development of angina pectoris during thyroid
replacement therapy is monitored, as this could have
important implications for future therapy. It is imaginable
that patients who are treated initially with a higher dose
of thyroxine will be euthyroid, and might feel better, much
sooner than patients treated according to the present
principle of starting low and increasing slow. Moreover,
elevated arterial blood pressure and high serum cholesterol,
both predisposing factors for coronary artery disease,
might decrease sooner.
C O N C L U S I O N
In conclusion, our data show that none of the cardiac
asymptomatic patients with untreated hypothyroidism
showed angina pectoris during stress testing and that no
signs of ischaemia were found in these patients. The 
precise role of hypothyroidism as a risk factor for coro-
nary artery disease should further be elucidated.
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A B S T R A C T
Background: To study the effects of two different structured
shared care interventions, tailored to local needs and
resources, in an unselected patient population with type 2
diabetes mellitus. 
Methods: A three-year prospective observational study of
two interventions and standard care. The interventions
involved extensive (A) or limited (B) task delegation from
general practitioners to hospital-liaised nurses specialised
in diabetes and included a diabetes register, structured
recall, facilitated generalist-specialist communication,
audit and feedback, patient-specific reminders, and
emphasised patient education. The target population
consisted of 2660 patients with type 2 diabetes treated in
the primary care setting. Patients who were terminally ill
or who had been diagnosed with dementia were excluded
from the study. 
Results: The participation rates were high (90%) for
patients, and none of the 64 GPs discontinued their
participation in the study. Longitudinal analyses showed
significant improvements in quality indicators for both
intervention groups (process parameters and achieved
target values on the individual patient level); in standard
care, performance remained stable or deteriorated.
Both patients and caregivers appeared satisfied with the
project.
Conclusion: This study shows that structured shared
care with task delegation to nurses, targeted at a large
unselected general practice population, is feasible and
can positively affect the quality of care for patients with
type 2 diabetes.
I N T R O D U C T I O N
Type 2 diabetes mellitus (type 2 DM) is a chronic disease,
which leads to considerable morbidity and premature
mortality.1,2 The prevalence of type 2 DM is high and is
increasing.3 Since most patients with diabetes die from
complications of atherosclerosis, they should receive
intensive preventive interventions to reduce their cardio-
vascular risk.4 Guidelines for clinical practice have been
developed in many countries to optimise diabetes care.5,6
However, the implementation of these guidelines has not
been straightforward.7,8 There are many reasons for this,
including a lack of time, recall facilities and diabetes
registers, staffing problems, poor quality of documentation,
the unavailability of qualified nurses, problems with
patient compliance, inadequate reimbursement, lack of
physician consultative assistance, and long waiting lists
for ophthalmologists.9,10
As in other countries, in the Netherlands the care for
type 2 DM patients is concentrated in the primary care
setting,6,11 and there is a growing shortage of primary
healthcare providers.12,13
Structured shared care can partially resolve the afore-
mentioned problems and may also improve the quality of
care for patients with diabetes.14 Multifaceted complex
interventions which target different barriers preventing
change are the most effective. Successful interventions
include applying organisational strategies that increase
structured recall, protecting time which has been reserved
for diabetes care, using multifaceted professional inter-
ventions, facilitating generalist-specialist communication,
delegating tasks to practice assistants or nurses and using
specialist diabetes nurse facilitators. Nurses can play an
important role in encouraging compliance and educating
© 2005 Van Zuiden Communications B.V. All rights reserved.
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patients. In certain situations, they can even replace
physicians in delivering many aspects of diabetes
care.9,10,14-16
Previous studies on diabetes care in general practice
have tended to include highly selected populations of
practitioners and patients.
Our aim was to study the effects of two different forms of
structured shared care, tailored to local needs and
resources, and of standard care in an unselected type 2 DM
patient population in a prospective observational study. 
M A T E R I A L S  A N D  M E T H O D S
Study design
The Zwolle Outpatient Diabetes project Integrating
Available Care (ZODIAC) study investigated the effects of
a shared care project for type 2 DM. In the Netherlands,
general practitioners (GPs) collaborate in GP working
groups. A GP working group consists of several GPs who
practice in the same area or town, and cover for each other
in the delivery of medical services during out-of-office
hours. Eight GP working groups (64 GPs) in the east of
the Netherlands agreed to participate in the study. Three
GPs were excluded from the study, two because they had
recently started a new practice and one due to retirement.
For pragmatic reasons, allocation to the two intervention
groups and to the standard care group was assigned
according to the preference of the GP working groups as
a whole. As Greenhalgh mentioned, it is important to
recognise that the different ways in which GPs organise
their diabetes care and in which they interface with
specialist services is a function of both the particular
needs of their practice populations and their individual
skills and confidence.14 Moreover, for interventions to work,
the methods must be acceptable to the target groups.17
The 32 GPs who participated in intervention A received
extensive support from nurses specialised in diabetes
(DSNs) who were hospital based, but who worked for the
project in the primary care setting. The second group
(intervention B, 21 GPs) received limited support from
DSNs, and the third group (intervention C, 8 GPs), the
standard care group, delivered standard care and received
no extra support. In this project, 1.6 full-time equivalent
DSNs were employed. 
I N T E R V E N T I O N S
Extensive support (intervention A) means that DSNs,
rather than the GPs, performed the annual examination
according to the national guidelines of the Dutch College
of General Practitioners for all the DM patients treated
in the primary healthcare setting. The GPs remained
responsible for the check-ups that should take place every
three months. On top of this, the DSNs gave one-on-one
education, tailored to the needs of the individual patients.
Fundus photography18 was integrated into the consultation
as well, where normally each patient would have been
referred to an ophthalmologist. If necessary (according
to retinal photography results, or in the case of a newly
diagnosed diabetes) a referral to the ophthalmologist was
arranged by the DSN. The appointments with the DSNs
took place outside the hospital in the primary healthcare
setting in the village or city where the patient lived. Any
patient who missed his or her appointment was rescheduled.
Patients who were housebound with serious comorbidity
were visited at home. A comprehensive structured report
of the results was sent to the GP within three weeks. 
If necessary, the results were accompanied by recommen-
dations from the DSN concerning referrals to a dietician,
chiropodist, and/or podiatrist, and by a recommendation
from an internist concerning treatment (according to the
guidelines). This process allowed the GPs to dedicate
their consultation time to discussing the results with the
patient in detail, and to decide how to act upon them.
The GPs kept the full responsibility for the care of the
patients and were not under any obligation to follow the
recommendations they were given. A second part of the
extensive support structure was the possibility of sending
individual patients directly to the DSN for an on-demand
consultation within the primary healthcare setting (without,
as in standard care, a formal referral to secondary care).
Possible reasons for requesting such a consultation could
be for patient education, instruction on self-monitoring, or
instruction on insulin injection. The GPs were responsible
for determining the initial insulin dosages and for making
any dosage changes. 
The only extraneous support the GPs in intervention
group B received was having direct access to on-demand
consultations with the DSN, without the need for a formal
referral to secondary care. They performed the annual and
three-monthly check-ups themselves, including making
any necessary referrals to the ophthalmologist.
In the standard care group (8 GPs), patient care was
delivered as usual, with no extra support. Consultation
with a DSN was only possible through a formal referral to
the internist in the secondary healthcare setting. 
All participating GPs received one-time feedback about
their baseline performance, which was discussed within
the GP working group in the presence of an internist.
Patients
The target population consisted of patients with type 2
diabetes who were being treated in the primary care setting,
and the aim was to have an unselected population.
Virtually all citizens of the Netherlands are registered
with a GP. Annually, the GPs provided lists with the
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names of all the patients who were known to have type 2
diabetes, as defined by the guidelines of the Dutch
College of General Practitioners.6 Patients with type 1
diabetes were excluded. Type 1 diabetes was defined by
age at diagnosis <40 years and a requirement for insulin
within one month of diagnosis. A total of 155,774 persons
were registered with the 61 participating GPs, 3362 of
whom had been diagnosed with type 2 diabetes mellitus.
Patients were only excluded if they were being treated in
secondary care by an internist, if they were terminally ill,
or if they had been diagnosed with severe dementia. 
Data collection
We collected data on all the eligible patients with type 2
DM who were registered with and were treated by the 61
GPs, during the three consecutive years from 1998 to
2000. The data were collected annually for all patients
from the (electronic and/or paper) patient records in the
general practice (including correspondence with specialists)
by the principal investigator of the study. Additionally,
data were collected by the investigator from the reports
on the consultations by the DSNs in the intervention
groups A and B. 
The data were collected on full medical history, micro-
vascular and macrovascular complications, diabetes and
other medication(s), referrals for ophthalmological
examination, measurements of blood pressure and
weight, foot examination, smoking status, and laboratory
measurements: HbA1c, total cholesterol, HDL cholesterol,
triglycerides, creatinine, microalbuminuria, and albumin-
creatinine ratio in urine (reference value for HbA1c 4.0 to
6.0%). The blood pressure was measured by the DSN in
intervention group A, and by the GP in intervention group
B and in the standard care group. The blood pressure was
measured twice with a Welch Allyn Sphygmomanometer
in the supine position after at least five minutes of rest.
Renal clearance was calculated by the Cockroft and Gault
formula.19 The data on patient and provider satisfaction
were collected by asking the GP ‘How do you judge the
shared care project?’ and ‘How do your patients judge the
shared care project?’ The Medical Ethics Committee of
the Isala Clinics (formerly Weezenlanden Hospital)
approved this study. 
Outcome measurements
The effects of the interventions were measured by
changes in three quality indicators. We studied (1) process
control (the percentage of patients with examinations and
measurements performed according to the guidelines),
and (2) outcome control (the percentage of patients who
achieved target values: HbA1c <7.0%, blood pressure
<150/85 mmHg, total cholesterol <5 mmol/l). Based on
available data, expressing the number of patients known
to have achieved target values as a percentage of the total
target population results in a quality indicator (3) that
combines process and outcome control. The feasibility of
the interventions was evaluated based on the participation
rates of the patients and the GPs and patient and provider
satisfaction. 
Analysis
Statistical analyses were performed using SPSS for
Windows. For baseline cross-sectional analyses we used
Student’s T-test, and the One-way Anova for variables
with a normal distribution, Mann-Whitney-U test for non-
normal variables, and the 2 test for categorical variables.
For longitudinal analyses we performed an ‘intention-
to-treat analysis’ and used the McNemar method. The
different groups were not directly compared with each
other because of the possible bias resulting from the non-
randomised design. 
R E S U L T S
The prevalence of diabetes in the study area was repre-
sentative for a larger area, and the size of the practice
population and the percentage of GPs working in solo-
practices were similarly representative for the population
of the Netherlands. None of the GPs discontinued their
participation in the study. 
Among the 2660 patients with type 2 diabetes treated in
the primary care setting (figure 1), 174 (6.5%) were excluded
by their GPs for reasons of terminal illness or dementia.
Altogether, 2486 patients were eligible for the study: 1244
were assigned to intervention group A, 842 to group B,
and 400 to the standard care group. 
Baseline data are shown in table 1. The three groups differed
significantly at baseline with respect to age, diabetes
duration, glycaemic control, cardiovascular risk factors, and
treatment. Patients who were excluded were older (77.3 vs
68.4 years), had more cerebrovascular complications (23 vs
11%), used significantly less antidiabetic, antihypertensive,
and lipid-lowering medication, and had their eyes (26 vs
55%) and feet (22 vs 36%) examined less frequently com-
pared with participants. 
Out of 2486 patients, 2048 (82%) were available for follow-
up after two years: 217 (8.7%) patients died, 154 (6.2%)
were referred to an internist, 66 (2.7%) moved, and two
patients were lost to follow-up. The referral percentages
to secondary care were 7% for group A, 4% for B, and
9% for the standard care group. The follow-up for the
different groups was 77% for intervention A, 88% for
intervention B and 79% for the standard care group. In
intervention A, 1121 (90.1%) of patients responded to the
invitation for a consultation with the DSN at least twice
during the three years of the project, and 33 (2.7%) were
excluded by the GP after initially participating. 
Ubink-Veltmaat, et al. Shared care with task delegation to nurses.
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Figure 1
Selection of patients with type 2 diabetes treated in primary care, assignment to the interventions in the ZODIAC
study, and follow-up between 1998 and 2001
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Baseline data from patients with type 2 diabetes treated in primary care in intervention groups A and B, and standard care
group C (means or percentages), 1998/1999
INTERVENTION GROUP STANDARD CARE 
A B C TOTAL P VALUE*
Practice characteristics
Gender GPs male (%) 88 85 100 89 0.52
Practice size 2612 2523 2732 2598 0.51
Prevalence DM (%) 1.9 2.3 2.4 2.1 0.09
Patients (N) 1127 842 400 2369
Gender female (%) 58 54 60 57 0.07
Age (years) 68.7 67.3 70.3 68,5 <0.001
Diabetes duration (years) 7.7 6.7 6.5 7.2 0.002
HbA1c (%) 7.5 7.3 7.3 7.4 0.01
BMI (kg/m2) 28.9 28.0 26.7 28.8 0.01
Systolic blood pressure(mmHg) 155 150 152 153 <0.001
Diastolic blood pressure (mmHg) 84 83 84 84 0.15
Total cholesterol (mmol/l) 5.7 5.5 5.9 5.7 0.003
Total cholesterol/HDL ratio 5.3 5.2 5.0 5.2 0.25
Diabetes treatment
Diet (%) 13 20 10 15 <0.001
Oral agent (%) 70 64 75 69
Insulin (%) 14 12 12 13
Insulin and oral agent (%) 2 5 3 3
*Single test for statistically significant differences between A, B, and C.
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The opportunity to consult with a DSN on-demand was
not frequently used. The reasons for these consultations
were, in the majority of cases, for support with respect to
education and instruction of insulin therapy within the
primary care setting: 27/47 (57%) for group A and 11/19
(58%) for group B.
The effects of the interventions are shown in tables 2 and 3.
Table 2 shows the change in process control. Performance
significantly improved with respect to process parameters
for both interventions A (extensive support by DSNs) and
B (limited support by DSNs): at two-year follow-up, all
examinations and measurements were performed more
frequently for group A, and most for B. In intervention A,
where the DSN is responsible for the annual check-up,
the performance was very high, ranging from 84 to 90%;
for intervention B this ranged from 18 to 85%. In the
standard care group, the performance regarding process
parameters remained stable or decreased, ranging from
2 to 72% for the various parameters after two years of
follow-up. Table 3 shows the change in outcome control:
Ubink-Veltmaat, et al. Shared care with task delegation to nurses.
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Table 3
Quality indicators for the treatment of patients with type 2 diabetes treated in primary care in intervention groups A
and B, and standard care group C in 1998/1999 and 2000/2001
PROCESS OUTCOME CONTROL PROCESS AND OUTCOME 
CONTROL BASELINE FOLLOW-UP P VALUE DIRECTION OF CONTROL COMBINED
GROUP (%) (%) (%) CHANGE# (%)*
HbA1c ≤7.0% A 89 43 42 0.76 - 37 (350/963)
B 75 46 48 1.0 - 36 (264/737)
C 63 50 42 0.03 ↓ 27 (84/314)
Blood pressure A 88 40 52 <0.001 ↑ 46 (439/963)
≤150/85 mmHg B 85 47 51 0.02 ↑ 44 (321/737)
C 72 43 42 0.92 - 30 (95/314)
Total cholesterol A 89 28 40 <0.001 ↑ 35 (341/963)
≤5 mmol/l B 63 33 49 <0.001 ↑ 31 (227/737)
C 39 26 26 0.27 - 10 (32/314)
*Known achieved target values in the total population (%); #p<0.05.
Table 2
Performance with respect to process control in the treatment of patients with type 2 diabetes treated in primary care in
intervention groups A and B, and standard care group C in 1998/1999 and 2000/2001
BASELINE (%) FOLLOW-UP (%) P VALUE DIRECTION OF SIGNIFICANT CHANGE
Foot examination A 44 87 <0.001 ↑
B 31 41 <0.001 ↑
C 16 11 0.11 -
Eye examination A 48 84 <0.001 ↑
B 57 67 <0.001 ↑
C 41 53 0.001 ↑
HbA1c A 57 89 <0.001 ↑
B 67 75 <0.001 ↑
C 62 63 0.91 -
Blood pressure A 76 88 <0.001 ↑
B 89 85 0.03 ↓
C 78 72 0.03 ↓
Total cholesterol A 46 89 <0.001 ↑
B 59 63 0.06 -
C 48 39 0.008 ↓
Creatinine A 54 89 <0.001 ↑
B 63 74 <0.001 ↑
C 60 63 0.33 -
Body mass index A 0.3 88 <0.001 ↑
B 0.3 18 <0.001 ↑
C 0.6 2 0.45 -
Smoking status known A 5 90 <0.001 ↑
B 25 41 0.001 ↑
C 7 11 0.001 ↑
performance regarding the percentage of patients who
achieved target values for the different groups. The per-
centage of patients with good glycaemic regulation
remained stable in intervention groups A and B, and
decreased in the standard care group. For both blood
pressure and hypercholesterolaemia, outcome control
improved in intervention groups A and B, while there
was no change in the standard care group. Based on the
available data, expressing the number of patients known
to have achieved target values as a percentage of the total
target population results in a quality indicator that com-
bines process and outcome control. It appears that the
performance for this quality indicator was 35 to 46% for
intervention A, 31 to 44% for intervention B, and 10 to
30% for the standard care group. 
The GPs rated the project as good in 70 and 69% of cases
and adequate in 30 and 25% of cases in interventions A
and B, respectively; the patients were satisfied in 81% of
cases according to their GPs. There was no mention of
dissatisfaction. 
D I S C U S S I O N
In this study, examining two interventions with structured
shared care and task delegation, which was targeted at an
unselected group of patients with type 2 diabetes treated
in a primary care setting, we found improvements in
process and outcome control. Performance for process
parameters increased for both interventions, as did the
percentage of achieved target values on the individual
patient level for blood pressure and total cholesterol, but
not for blood glucose control. In contrast, the standard
care group showed minimal improvements, and even
some deterioration. The patient participation rate
remained high throughout the study, and none of the
GPs discontinued participation. 
Strengths and limitations
A strong point of this study is that the results may, for the
most part, be generalised to similar patient populations.
We studied a highly unselected patient population, unlike
many of the previous studies on this topic. The quality of
care improved even though changes are difficult to effect in
busy primary care environments.20 The interventions used
in this study may be used in other primary care settings,
provided the same exclusion criteria are applied.
Excluding those terminally ill or having dementia seems
realistic from a clinical point of view: intensive therapy is
either not useful for prevention of long-term complications
or not possible.21
A limitation of our study is the nonrandomised design.
To study how evidence and guidelines may be translated
into daily practice, flexibility is necessary to deal with
pragmatic issues; rigorous nonrandomised study designs
including quasi-experimental, time series and observational
studies are sometimes more appropriate.22 We chose, for
pragmatic reasons, to assign the patients to the intervention
groups according to the preferences of the GP working
groups. The effects of the interventions may have been
overestimated as a consequence of the design,23 and base-
line values were not comparable for the three groups
analysed. Direct comparison would consequently be difficult
to interpret. We therefore decided to limit our analysis to
independent descriptions of the three intervention groups,
and focussed on the quality indicators at the individual
patient level instead of on group means. At the same
time, there was a difference in the amount of available
data: in group A the data collected during consultations
with the patients by the DSNs were nearly complete. In
groups B and C, however, the data were collected from
the GPs’ patient records, where the availability of data
was not optimal. Obtaining data provided from medical
records can lead to underreporting of care delivered.24
However, although the same lack of documentation has
been found by others,20,25 and intermediate outcomes
may not be different for the patients concerned,25 the
negligent recording of risk factors reflects suboptimal
care, because opportunities to detect increased risk and
therefore to start treatment are missed. Moreover, the
quality of care delivered lacks transparency. 
Comparison with other studies
With intervention A (extensive support by DSNs) a large
increase was found with respect to process control, with
an overall high performance rate between 84 and 90%,
which is higher than that found in another recent study
(41 to 80%).25 This appears to be a direct effect of the
central role of the DSNs who were responsible for per-
forming the annual check-up. For intervention B (limited
support by DSNs), process control improved as well, and
was comparable with, or higher than (but still suboptimal)
the findings reported by Goudswaard et al.25 The standard
care group showed few improvements, and even some
deterioration. Renders et al. reported a similar finding for
their reference group.26
For outcome control (achieved target values), in both
intervention groups the percentage of patients achieving
target values increased for blood pressure regulation and
lipid control. Although difficult to compare, other inter-
vention studies with a central role for DSNs showed
improvement in blood pressure and/or lipid profile as
well,27-29 whereas programmes without a central role for
DSNs found no (significant) positive effect on these
outcomes.26,30 In the standard care group no changes in
outcome control for blood pressure or hypercholesterol-
aemia were found.
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In the intervention groups we did not find an increase in
the percentage of patients with good glycaemic regulation,
whereas other intervention programmes did.27,29-32 The
percentage of patients with an HbA1c <7 is comparable or
somewhat lower compared with that found by others.26,30,32
An explanation for the lack of improvement may be that
the baseline HbA1c was already quite acceptable in this
unselected population, which may have left little room
for improvement (ceiling effect).33 The GPs in all three
participating groups treat a higher percentage (80%) of
the total diabetic population in primary care than in most
other programmes (61 to 75%),26,34,35 probably also including
a higher percentage of patients who are difficult to treat.
Since metabolic control tends to deteriorate with the
duration of the disease,36 keeping glycaemic control stable
could be seen as a positive effect of the interventions. In
the standard care group, the percentage of patients with
good glycaemic regulation decreased, which was also
reported by De Sonnaville et al. for their control group.30
Using a quality indicator that combines process and
outcome control may be a simple and transparent
method to indicate the quality of care delivered, enabling
benchmarking of performance at the level of the individual
health care providers or teams.
In intervention group A, 9.9% of patients did not visit
the DSN in either one of the three project years. This
percentage seems acceptable as it is within the variance
(0 to 17%) that is mentioned in a Dutch literature study
into diabetes patients not showing up within a period of
6 to 13 months.37 Reasons mentioned by patients varied
between ‘just don’t want to’ and ‘long-term admittance to
the hospital’ or ‘partner to ill’ or ‘family problems’. Many
patients who could not participate in one year resumed
participation in the next year. 
The follow-up period may have been too short to show all
the potential positive effects, since the GPs only started to
make more use of on-demand consultations after two years.
We expect that the intervention groups and the standard
care group will diverge further with respect to the quality
of care as, in intervention group A, the recommendations
from the internists become increasingly stringent and
extensive at the GPs’ request. Moreover, we are currently
seeing a large annual increase in on-demand consultations
in intervention groups A and B.
Implications
Abnormal but unrecorded values deprive the GP of possible
indications for starting or adjusting treatment, and may
therefore hamper the achievement of optimal diabetes
care at the individual patient level. Moreover, unrecorded
values limit the transparency of the care delivered. In
other healthcare settings, quality indicators have yet to be
included in the assessment of the quality of diabetes care.38
Although there have been proposals,39,40 in the Netherlands
there is not yet an official set of quality indicators, while
this would be useful for benchmarking and to compare
effect evaluations of interventions to improve the quality
of diabetes care. 
The delegation of tasks to nurses appears to improve
process control, as process indicators improved and
reached high levels when nurses were responsible for
performing the annual check-ups. Concomitantly, outcome
control appears to improve at the level of individually
reached target values. 
Ultimate proof of the effectiveness of these interventions
can only be seen after analysing the development of
complications as was done recently by Gaede et al.41
The ZODIAC study has now entered its seventh year
which will make the assessment of long-term effects of
the presented interventions possible within the next
few years.
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C A S E  R E P O R T
A 66-year-old man was admitted to our hospital because of dyspnoea and slightly elevated body temperature (38.1°C). 
A month before admission the patient suffered an ischaemic cerebrovascular accident. His medical history also revealed
a myocardial infarction seven years ago and a transient ischaemic attack.  
On physical examination his blood pressure was 130/80 mmHg, pulse 102 beats/min and regular; the central venous
pressure was clearly elevated. The respiratory rate was 36 breaths/min. Examination of the lungs and heart revealed no
abnormalities. The right lower extremity was red, warm and swollen and painful on palpation.
Laboratory tests were performed. An arterial blood sample showed no abnormalities. Lactate dehydrogenase was 566
U/l and troponin I 0.51 g/l. A chest X-ray showed no abnormalities. His electrocardiogram (ECG) is shown in figure 1. 
© 2005 Van Zuiden Communications B.V. All rights reserved.
M A R C H  2 0 0 5 ,  V O L .  6 3 ,  N O .  3
111
P H O T O  Q U I Z
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Figure 1
12-lead electrocardiogram of the patient
W H A T  I S  Y O U R  D I A G N O S I S ?
See page 118 for the answer to this photo quiz.
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A B S T R A C T
This case report describes a 61-year-old rheumatoid
arthritis patient with an atypical clinical presentation of
a sore throat. Because of rheumatoid arthritis refractory
to conventional disease-modifying antirheumatic drug
therapy, anti-TNF was felt to be indicated, and a screening
for tuberculosis was carried out. As the screening for
tuberculosis (PPD) was positive, isoniazid was prescribed
prophylactically for six months. After eight months of
anti-TNF (adalimumab) treatment, he developed tonsillar
enlargement and nodular pulmonary lesions. Histo-
pathological and microbial investigations established the
diagnosis of tonsillar tuberculosis.
I N T R O D U C T I O N
Tumour necrosis factor  (TNF) is a cytokine that plays
an important role in the regulation of inflammatory
processes. The proinflammatory cytokine TNF, which
is released by activated monocytes, macrophages and T
lymphocytes, promotes inflammatory responses that are
important in the pathogenesis of rheumatoid arthritis.
Rheumatoid arthritis patients have high TNF levels in
the synovial fluid and subsequently develop bone erosion.
Drugs blocking TNF have been developed to neutralise
these effects and to improve symptoms significantly.1 One
of these blocking agents is adalimumab (Humira), a
recombinant human immunoglobulin G1 monoclonal
antibody.2
Inhibition of TNF is associated with the risk of developing
a serious infectious disease3,4 as well as difficulty clearing
infections once they have developed. One of the pathogens
known to be capable of causing invasive disease in
patients receiving TNF blockade therapy is Mycobacterium
tuberculosis.5 TNF in a soluble form increases the
expression of adhesion molecules on endothelial cells
and activates neutrophils and macrophages. Surface-bound
TNF is likely to be involved in cell-to-cell interactions,
potentiating the activation of specific and nonspecific
immune effector cells. The production of TNF by alveolar
macrophages has been shown to be essential in granuloma
formation, chemokine production, leucocyte recruitment
and the killing of intracellular pathogens, such as
Mycobacterium tuberculosis.6
The purpose of this report is to point out that by applying
modern anti-TNF therapies we should increase awareness
of potential complications such as tuberculosis, including
extrapulmonary lesions, even when a patient follows the
screening procedure and adheres strictly to a prophylactic
treatment regimen for a period of six months.
C A S E  R E P O R T
A 61-year-old man visiting the rheumatology outpatient
department for a routine check-up presented with a two-
month history of sore throat, cough, fever, loss of appetite
and weight loss of 10 kg. Two different antibiotics prescribed
by his general practitioner did not relieve the symptoms.
After 11 years of rheumatoid-factor-positive rheumatoid
arthritis, he became refractory to treatment with sulpha-
salazine (2000 mg daily) and (parenteral) methotrexate
(25 mg weekly). There was no history of prior infection,
foreign travel or infectious contacts. He was married, worked
as a construction labourer, smoked and consumed small
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© 2005 Van Zuiden Communications B.V. All rights reserved.
C A S E  R E P O R T
Tonsillar tuberculosis in a rheumatoid 
arthritis patient receiving anti-TNF
(adalimumab) treatment
M.N. Efde, P.M. Houtman*, J.P.L. Spoorenberg, T.L.Th.A. Jansen
Department of Rheumatology, Leeuwarden Medical Centre, Leeuwarden, the Netherlands, 
tel.: +31 (0)58-286 61 04, fax: +31 (0)58-286 61 05, e-mail: p.m.houtman@wxs.nl, 
*corresponding author
M A R C H  2 0 0 5 ,  V O L .  6 3 ,  N O .  3
113
amounts of alcohol. For optimal suppression of the rheuma-
toid inflammation, a TNF-blocking agent was indicated. 
Prescreening for tuberculosis revealed a normal chest radio-
graphy but positive skin testing (10 tuberculosis units PPD)
showing an induration of 4 x 4 cm. Bronchoalveolar lavage
did not show active infection with tuberculosis. Ziehl-
Neelsen staining and microbiological culture were negative.
Despite these results prophylactic treatment with a regimen
of isoniazid 300 mg daily for a period of six months was
started. After five months of isoniazid, adalimumab 40 mg
subcutaneously once every two weeks was started. His
rheumatoid arthritis significantly improved: he was a
good responder according to the DAS28 criteria.7
Seven months after the start of adalimumab and five
months after the cessation of isoniazid the patient
became ill. Chest radiography on a routine visit two
months later showed nodular abnormalities (figure 1) and
oral examination showed unilateral left tonsil enlargement.
As malignancy was suspected a tonsil biopsy was per-
formed. Histology revealed no malignancy but only vague
granulomatous structures composed of central caseation
necrosis with bacilli suspicious for mycobacteria.
Polymerase chain reaction (PCR in-house)8 gene probe
demonstrated Mycobacterium tuberculosis complex.
Sputum, bronchoalveolar lavage and tonsillar tissue were
all negative for acid-fast bacilli by Ziehl-Neelson staining.
Subsequently, cultures of these samples revealed
Mycobacterium tuberculosis (INH susceptibility positive). 
Computed tomography confirmed lymphadenopathy in
the neck region, mediastinum and upper abdomen.
Tonsillar tuberculosis was diagnosed, probably secondary
to pulmonary disease. The patient was placed on a regimen
of isoniazid (300 mg daily), rifampicin (600 mg daily),
ethambutol (400 mg daily) and pyrazinamide (500 mg
daily). The patient was free of symptoms within three
weeks. Adalimumab and methotrexate treatment were
both stopped for the next six months. The tonsillar
enlargement as well as the pulmonary lesions subsided.
The rheumatoid arthritis remained in remission by
applying sulphasalazine monotherapy.
D I S C U S S I O N
This case illustrates tonsillar tuberculosis as a sequel of
anti-TNF therapy. It is important to stress the atypical
presentation of this severe opportunistic infection in
anti-TNF treated patients: the symptoms may mimic a
conventional throat infection. Tuberculosis secondary to
adalimumab has not yet been reported to the Netherlands
Pharmacovigilance Centre (personal communication).
The diagnosis was made by identifying acid-fast bacilli in
the tonsil biopsy material and confirmed by PCR.
Tuberculosis observed after anti-TNF therapy may be
due to failure of compartmentalisation of viable
Mycobacterium tuberculosis bacilli and therefore granulomas
may not be seen. This patient may well have become ill
due to an inadequate prophylaxis of six months for his
latent tuberculosis. The extrapulmonary tuberculosis in
this patient is probably secondary to primary pulmonary
localisation although we have no data, i.e. microbiological,
on the pulmonary abnormalities except for the nodular
interstitial findings on chest radiography and computer-
ised tomography. These interstitial findings subsided
during and after treatment of the tuberculosis. In this
patient the most likely period for acquiring the latent
tuberculosis infection was the second world war.
Tuberculosis in patients receiving anti-TNF therapy
generally arises from the reactivation of latent infection
and usually occurs within the first three to eight months
of treatment. In a previous study of adalimumab therapy,
tuberculosis developed in eight out of 542 patients.
The introduction of screening procedures and the use of
lower doses of adalimumab reduced the frequency to five
out of 1900 patients.9
The proportion of extrapulmonary and miliary cases, up
to 40% of anti-TNF therapy induced reactivation of
tuberculosis, is similar for all TNF antagonists.10 Just
prior to the era of TNF blockade, oral manifestations of
tuberculosis occurred sporadically and usually secondary
to pulmonary disease.10,11 So far one case of tuberculous
Efde, et al. Tonsillar tuberculosis in a rheumatoid arthritis patient.
Figure 1
Chest X-ray showing nodular abnormalities, more pro-
nounced in the upper than in the lower parts of the lungs
tonsillitis in a patient receiving etanercept has been
reported.12 Tuberculosis is not associated with the use of
low-dose corticosteroids (i.e. prednisone at doses of 15 mg
or less) and cytotoxic agents in rheumatic diseases.13,14
In June 2003 official Dutch guidelines for rheumatologists
for prevention of tuberculosis in rheumatoid arthritis
patients treated with anti-TNF therapy were established.15
The screening procedure includes, in addition to medical
history and physical examination, intracutaneous testing
and chest radiography. A subpopulation of immuno-
compromised patients may be anergic and may reveal a
false-negative skin screening test. 
If the screening reveals a latent infection, prophylactic
treatment with isoniazid 300 mg daily for a period of at
least nine months is now recommended. The effectiveness
of isoniazid has been confirmed in randomised clinical
trials and it can afford protection in up to 69 and 93% of
those who strictly comply for six and nine months,
respectively.16,17 Prophylactic treatment should be given for
at least three months before starting the TNF blocking
agent. The duration of isoniazid treatment turned out to
be inadequate for the latent tuberculosis in the presented
patient, immunocompromised by the treatment with
immunomodulating drugs for his rheumatoid disease.
An additional factor may be that the mycobacterium may
have become resistant to isoniazid. 
Studies indicate that other chronic inflammatory diseases,
for example severe psoriasis, will benefit from anticytokine
therapy as well. An increasing number of specialists will
probably treat patients in the near future with anti-TNF
for an increasing number of indications. Given the highly
effective reduction in disease activity achieved by these
agents some adverse outcome should probably be accepted.
However, patient and physicians must be aware that
during anti-TNF therapy the course of infections may
be fulminant and life threatening. In addition, clinical
and laboratory signs may be blunted by TNF blockade
and by concomitant immunosuppressive medication.
Therefore, only specialists familiar with the indications as
well as the increased risks of tuberculosis and other
opportunistic infections should prescribe these potent
agents. Careful evaluation at the initiation of the treat-
ment as well as long-term surveillance of the patients
receiving such drugs remains necessary: patient selection,
education and safety monitoring should maximise patient
safety. 
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A B S T R A C T
Perianal tuberculosis, without the presence of any previous
or active pulmonary infection, is extremely rare. A case of
isolated perianal tuberculosis without gastrointestinal or
pulmonary spread will be discussed here with an evaluation
of the clinical features.
I N T R O D U C T I O N
The incidence of pulmonary tuberculosis has decreased
and extrapulmonary tuberculosis has become very rare
with the introduction of effective antituberculous
chemotherapy. However, although the rates of mortality
and morbidity due to tuberculosis are decreasing, it has
been reported that there is an increase in the cases of
tuberculosis due to the increasing incidence of acquired
immune deficiency syndrome (AIDS).1 On the other hand,
perianal tuberculosis, without the presence of previous or
active pulmonary infection, is extremely rare. Here, we
present a case of isolated perianal tuberculosis without
gastrointestinal or pulmonary spread. 
C A S E  R E P O R T
An 80-year-old male patient was admitted with a history
of perianal discharge and ulceration for the last six months.
Treatment with topical antibiotics and epithelialising oint-
ment had been ineffective. The patient was afebrile on
admission. No lymphadenopathy was found on palpation,
and physical examination of the respiratory tract was
normal. No palpable mass or organomegaly was detected
on abdominal examination. 
There was an ulceration in the left perianal region with a
transverse diameter of 4 cm and vertical diameter of 3 cm
(figure 1). Digital rectal examination revealed no pathological
findings. Anoscopy was normal and no fistulas were
noted. Laboratory studies showed normal values of
haemoglobin, haematocrit, total leucocyte count, platelets
and erythrocyte sedimentation rate. Liver enzymes and
renal function tests were also within the normal range.
Chest X-ray revealed no pathological findings.
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Figure 1
An ulceration in the left perianal region at line 7 by 
proctological position, starting 2 cm from the anus, with
a transverse diameter of 4 cm and vertical diameter of 
3 cm was observed on admission
The perianal lesion was curetted and biopsy material was
taken. Since only nonspecific granulation was found in the
first biopsy, a second biopsy was performed a week later.
Histological examination of the second biopsy showed
epithelioid granulomas, Langhans’ type multinucleated giant
cells, caseous necrosis, and acid-fast bacilli. In addition,
polymerase chain reaction (PCR) was positive for myco-
bacterium tuberculosis. A PPD test revealed a negative
reaction with 4 mm of induration. PCR assays of the
sputum collected on three subsequent days were negative
for tubercle bacilli. Double-contrast barium studies of colon
and small bowel were normal. No pathological findings
were detected on upper gastrointestinal endoscopy and
rectosigmoidoscopy. Computed tomography of the
abdominal and pelvic region revealed no pathological
findings either. Human immunodeficiency virus antibody
test was negative.
We made a diagnosis of isolated perianal tuberculosis and
started triple antituberculous treatment consisting of iso-
niazid (300 mg/day), rifampicin (600 mg/day), and
pyrazinamide (2 g/day) No side effects occurred. His
symptoms resolved and the perianal ulcer began to heal
within the first month of treatment (figure 2). From the
culture of the biopsy specimen, tubercle bacilli were isolated
on Lowenstein-Jensen medium in the eighth week of
D I S C U S S I O N
We present here a case of perianal tuberculosis in an
elderly patient without HIV infection. The incidence of
tuberculosis of the gastrointestinal tract has dramatically
decreased in the last few decades. Development of anti-
tuberculosis chemotherapies and widespread use of
pasteurised milk have played a major role in this decrease.
In addition, better recognition of Crohn’s disease prevents
it from being misdiagnosed as gastrointestinal tuberculosis.
However, tuberculosis of the gastrointestinal tract is still
present in developing countries, particularly in large
migratory communities. Recently, the number of cases of
tuberculosis has shown a tendency to increase with the
rising number of cases with AIDS in developed countries.1
Extrapulmonary tuberculosis is responsible for 15% of all
cases of tuberculosis. Extrapulmonary spread mainly con-
sists of involvement of the pleura (26%), lymph nodes
(17%), genitourinary tract (15%), bones and joints (14%),
meninges (6%), peritoneum (4%) and miliary TB (8%).2,3
Tuberculosis of the gastrointestinal tract is responsible for
1% of all cases of tuberculosis. Tuberculosis may involve
any part of the gastrointestinal system, such as the peri-
toneum, stomach, duodenum, ileocaecal region, colon,
rectum, and anus. Of these, tuberculous peritonitis is the
most common.2 The most frequently affected part of
intestinal tract is the ileocaecal region. Involvement of the
appendix and jejunum is uncommon, and spread to the
anus is much rarer.4 Tuberculosis of the gastrointestinal
tract usually occurs as a result of spread from tuberculosis
foci in the lungs. Ingestion of the bacilli from sputum
may lead to invasion of the intestinal wall. Harland et al.
presented two cases diagnosed as anal tuberculosis
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Figure 2
Healing of the ulcer within the first month of 
antituberculous treatment
Figure 3
Recovery of the lesion (only a mild granular region was
observed at the same localisation at the sixth month of
the treatment)
treatment. Therapy with isoniazid and rifampicin was
continued for six months. After six months, the lesion
had disappeared, and only a mild granular region
remained (figure 3). The patient is healthy without any
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associated with pulmonary tuberculosis.5 Sultan et al.
documented data of seven cases of anoperineal tuberculosis
observed between 1982 and 1999, and an association
with pulmonary tuberculosis was found in each case.6
However, pulmonary tuberculosis may not be present and
intestinal and peritoneal disease may develop by reactivation
of the latent focus. Other mechanisms that have been
considered are haematogenous spread and retrograde
spread of M. tuberculosis into abdominal lymph nodes
from a pulmonary site.7 In our patient, no pulmonary or
gastrointestinal focus was found despite an extensive
investigation. 
Perianal tuberculosis may manifest as an ulcerative, ver-
rucous, lupoid and miliary form. The most common type
is the ulcerative lesion which tends to have well-defined
boundaries and be characterised by mucopurulent dis-
charge. The verrucous type tends to extend into the anal
passage from the perianal region with a development
pattern similar to that of a wart. However, it may appear as
a haemorrhoidal nodule, perianal abscess or anal fistula.7,8
Our patient presented with perianal ulceration, and no
abscess or anal fistula was noted. 
Crohn’s disease plays a significant role in the differential
diagnosis of perianal tuberculosis, and other conditions
that should be considered are ulcerative colitis, herpes
simplex lesions, syphilis, sarcoidosis, amebiasis, deep
mycosis, lymphogranuloma venereum, and ulcerative
neoplasms.7,9 Differentiating between perianal tuberculosis
and Crohn’s disease may be difficult. Both conditions
have certain similar features including colonic skip
lesions, ileocaecal spread and granulomas on histological
examination. These two diseases may be difficult to dis-
tinguish from each other by macroscopic evaluation, and
microscopic examination is needed. When tuberculosis is
considered, a biopsy needs to be taken from the lesion;
acid fast staining and if available polymerase chain reaction
should be used for a rapid and accurate diagnosis.
Finally cultures are needed to confirm the diagnosis and
susceptibility testing. 
C O N C L U S I O N
In conclusion, since it is an extremely rare aetiological
cause in patients with anal discharge and ulceration, the
diagnosis of perianal tuberculosis is difficult to make when
there is no pulmonary focus. It has to be kept in mind
that cases of perianal tuberculosis may appear as incipient
disease without the presence of any previous or active
pulmonary infection. Tuberculosis has to be considered in
the differential diagnosis of perianal ulcers since treatment
with antituberculous agents may provide complete recovery. 
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D I A G N O S I S
The ECG showed a sinus tachycardia of 111 beats/min, an incomplete right bundle branch block and a so-called
McGinn-White S1Q3T3 pattern.1 There were no signs of acute ischaemia. 
Because a pulmonary embolism was considered, a high-resolution spiral computed tomography angiography was per-
formed.2 This showed a massive pulmonary embolism presenting as a classic saddle embolus at the bifurcation of the
main pulmonary artery extending into the left and right pulmonary arteries (figure 2).
A transthoracic echocardiography was performed which showed dilatation of the right ventricle with tricuspid regurgita-
tion and systolic pulmonary artery hypertension of 58 mmHg, compatible with massive pulmonary embolism.3
The patient was treated with intravenous heparin/low-molecular-weight heparin and acenocoumarol. Because of a
recent cerebrovascular accident we considered thrombolytic therapy to be contraindicated.4,5 After eight days the patient
was discharged. During follow-up the patient remained asymptomatic.
Classic features of massive pulmonary embolism at electrocardiography1 and echocardiography3: 
- Sinus tachycardia
- (Incomplete) right bundle branch block
- McGinn-White S1Q3T3 pattern, which means S wave in lead I, Q wave in lead III and a flattened or negative T wave
in lead III
- Right ventricular dilatation and systolic pulmonary hypertension
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Figure 2
High-resolution spiral CT-scan angiography presenting
the saddle embolus 
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